11␤-Hydroxysteroid dehydrogenase type 1 (11␤-HSD1) interconverts inactive cortisone and active cortisol. Although bidirectional, in vivo it is believed to function as a reductase generating active glucocorticoid at a prereceptor level, enhancing glucocorticoid receptor activation. In this review, we discuss both the genetic and enzymatic characterization of 11␤-HSD1, as well as describing its role in physiology and pathology in a tissue-specific manner. The molecular basis of cortisone reductase deficiency, the putative "11␤-HSD1 knockout state" in humans, has been defined and is caused by intronic mutations in HSD11B1 that decrease gene transcription together with mutations in hexose-6-phosphate dehydrogenase, an endoluminal enzyme that provides reduced nicotinamide-adenine dinucleotide phosphate as cofactor to 11␤-HSD1 to permit reductase activity. We speculate that hexose-6-phosphate dehydrogenase activity and therefore reduced nicotinamide-adenine dinucleotide phosphate supply may be crucial in determining the directionality of 11␤-HSD1 activity. Therapeutic inhibition of 11␤-HSD1 reductase activity in patients with obesity and the metabolic syndrome, as well as in glaucoma and osteoporosis, remains an exciting prospect.
T WO ISOZYMES OF 11␤-hydroxysteroid dehydrogenase
(11␤-HSD1 and 11␤-HSD2) catalyze the interconversion of hormonally active cortisol and inactive cortisone. Although the type 1 or "liver" isozyme was the first to be characterized, it was the type 2 or "kidney" isozyme that gained most acclaim in the late 1980s to mid-1990s because of its link to an inherited monogenic form of hypertension, apparent mineralocorticoid excess. The physiology and pathophysiology of 11␤-HSD2 and its link to human hypertension have been covered in this Journal in an excellent review by White et al. (1) .
The last decade has seen an exponential increase in research focusing on 11␤-HSD1, principally because of its putative role in human obesity and insulin resistance, but also in other diseases in which glucocorticoids have historically been implicated (osteoporosis, glaucoma). These clinical studies have been underpinned by studies in vitro and the manipulation of enzyme expression in vivo using recombinant mouse models. Finally, the molecular basis for the putative human 11␤-HSD1 knockout-cortisone reductase deficiency (CRD)-has recently been described, an observation that also answers a long-standing conundrum relating to the enzymology of 11␤-HSD1.
II. Cortisol Metabolism and History of 11␤-HSD1
Functionally, adrenal corticosteroids have been divided into two distinct classes, glucocorticoids and mineralocorticoids. Glucocorticoids (cortisol, corticosterone) exert a diverse array of physiological roles including the regulation of carbohydrate and amino acid metabolism, maintenance of blood pressure, and modulation of the stress and inflammatory responses (2) . In contrast, mineralocorticoids (aldosterone) principally stimulate epithelial sodium transport (3) . Both classes of corticosteroid hormone exert their effects through binding to intracellular receptors [glucocorticoid and mineralocorticoid receptors (GR, MR)] with subsequent stimulation or repression of target gene transcription.
Cortisol is the principal circulating glucocorticoid in man and is secreted under the control of the hypothalamo-pituitary-adrenal (HPA) axis. Aldosterone, which is secreted from the outer zona glomerulosa predominantly under the control of the renin-angiotensin system through angiotensin II, is the principal mineralocorticoid in man. Glucocorticoids are secreted in relatively high amounts [cortisol, 15 mg/d (4, 5) , corticosterone, 2 mg/d (6) ] and mineralocorticoids are secreted in low amounts [aldosterone, 150 g/d (7)].
More than 90% of circulating cortisol is bound, predominantly to the ␣ 2 -globulin, cortisol-binding globulin. Only the free fraction is biologically active; the excretion of this "free" cortisol through the kidneys is termed urinary free cortisol (UFF) and represents only 1% of the total cortisol secretion rate. The circulating half-life of cortisol varies between 70 and 120 min. The major steps for cortisol metabolism are:
1. The interconversion of the 11-hydroxyl (cortisol, Kendall's compound F) to the 11-oxo group (cortisone, compound E) through the activity of 11␤-hydroxysteroid dehydrogenase (EC 1.1.1.146) (8, 9) . The metabolism of cortisol and cortisone then follow similar pathways.
2. Reduction of the C4 -5 double bond to form dihydrocortisol (DHF) or DHE followed by hydroxylation of the 3-oxo group to form tetrahydrocortisol (THF) and tetrahydrocortisone (THE). The reduction of the C4 -5 double bond can be carried out by either 5␤-reductase or 5␣-reductase to yield, respectively, 5␤-THF (THF) or 5␣-THF (allo-THF) (10) . In normal subjects, the 5␤-metabolites predominate (5␤-THF: 5␣-THF, 2:1). THF and THE are rapidly conjugated with glucuronic acid and excreted in the urine (11) .
3. Additional reduction of the 20-oxo group by either 20␣-or 20␤-HSD to yield ␣-and ␤-cortols and cortolones from cortisol and cortisone, respectively. Reduction of the C-20 position may also occur without A ring reduction giving rise to 20␣-and 20␤-hydroxycortisol (12). 4 . Hydroxylation at C-6 to form 6␤-hydroxycortisol. 5 . Cleavage of THF and THE to the C 19 steroids 11-hydroxy-or 11-oxo-androsterone or etiocholanolone.
6. Oxidation of the C-21 position or cortols and cortolones to form the extremely polar metabolites cortolic and cortolonic acids (13) .
Approximately 50% of secreted cortisol appears in the urine as THF, allo-THF, and THE; 25% as cortols/cortolones; 10% as C 19 steroids; and 10% as cortolic/cortolonic acids. The remaining metabolites are free, unconjugated steroids (cortisol, cortisone, 6␤-and 20␣/20␤-metabolites of cortisol and cortisone) (14) .
Although some cortisone may be secreted by the adrenal (15) , circulating cortisone concentrations are principally dependent upon "oxidative" 11␤-HSD2 and are approximately one fifth those of cortisol (ϳ60 nmol/liter). However, because of the lower binding affinity to cortisol-binding globulin, free cortisone concentrations are similar to those of free cortisol (16, 17) .
The biological activity of any glucocorticoid relates, in part, to the presence of a hydroxyl group at position C-11 of the steroid structure. Cortisol and the principal glucocorticoid in rodents, corticosterone, are active steroids whereas cortisone and 11-dehydrocorticosterone, possessing a C-11 keto group, are inactive. Thus, any tissue expressing 11␤-HSDs can regulate the exposure of that tissue to "active" glucocorticoid.
In retrospect, the first appreciation of 11␤-HSD activity came through the discovery by Kendall (18) of cortisone and elucidation of its potent antiinflammatory activity in patients with rheumatoid arthritis. Unbeknownst to him at the time, he had discovered an "inactive" hormone; bioactivity was dependent upon 11␤-HSD activity in the liver, activating cortisol from cortisone. Subsequently, cortisol was characterized as the active ligand, and shortly thereafter the first description of tissues converting cortisol to cortisone was published. These early studies demonstrated significant amounts of 11␤-HSD activity in human placenta (19) , kidney (20) , and liver (21) , although the "set point" of the enzyme varied, with oxidative activity (F to E) predominating in the placenta and kidney and reductive (E to F) in the liver. Isotopic studies (22) and clinical studies measuring F/E levels in patients with renal disease (23, 24) confirmed that the kidney was an important site for cortisol to cortisone conversion. Selective venous catheterization studies indicated significantly lower circulating F/E ratios in renal venous blood compared with peripheral values. In contrast, circulating F/E ratios were much higher in hepatic venous blood, confirming that the liver predominantly converts cortisone to cortisol (25) . This is explained by the activity of two distinct isozymes of 11␤-HSD, a predominantly reductive nicotinamide-adenine dinucleotide phosphate reduced (NADPH)-dependent type 1 or "liver" isozyme and a NADdependent oxidative type 2 or "renal" isozyme.
The contributions of these isozymes to global cortisolcortisone interconversion can be assessed clinically through gas chromatographic/mass spectrometry analysis of the principal urinary cortisol and cortisone metabolites. Thus, the ratio of UFF/urinary free cortisone (UFE) accurately reflects the activity of renal 11␤-HSD2. If this ratio is normal, then the ratio of urinary tetrahydrocortisols (5␣-THF or allo-THF and 5␤-THF) to tetrahydrocortisone (THE) is a useful marker of 11␤-HSD1 activity (26) . Other workers extend this ratio to include all cortisol and cortisone metabolites (Fm/Em ratio: THF, allo-THF, cortols, cortisol/THE, cortolones, and cortisone) (27) (28) (29) (30) .
III. Short-Chain Dehydrogenases/Reductases (SDRs) and Enzymology of 11␤-HSD1
A. The SDR superfamily 11␤-HSD1 belongs to the SDR superfamily, a well-established enzyme family of oxidoreductases, distinct from zinccontaining alcohol dehydrogenases (31, 32) , iron-containing dehydrogenases (32) , aldoketo-reductases (33) , and medium-chain dehydrogenases/reductases (34) . Also known as short-chain alcohol dehydrogenases (35) or sec (secondary) alcohol dehydrogenases (36) , members of this family were originally classified as having 250 -300 residues (classical family) with an N-terminal cofactor-binding domain and a centrally located active site, although some enzymes now have more than 400 residues (extended family) (37) . These families are now distinguished further into three subfamilies (intermediate, divergent, and complex), based on patterns of charged residues within the cosubstrate-binding region (38) .
At present, around 3000 members of this family have been identified through the occurrence of several distinct sequence motifs highlighted in Table 1 (35, (37) (38) (39) (40) (41) . These primary structure features form essential parts of the nucleotide cofactor-binding region (Rossmann-fold) and the active site (37, 40) .
The nucleotide cofactor-binding region characterized by GXXXGXG confers specificity to NADPH and is highly conserved within the family (40) , although the presence of dehydratase and epimerase reactions utilizing other cofactors within the family explains why many of the residues found in the motifs are not completely conserved within the entire family (37) . The active site of these enzymes contains invariant tyrosine (Y) and lysine (K) residues, although adjacent serine (S) residues are also highly conserved, and this denotes the catalytic triad. An analysis of 116 active site motifs in SDR family members from the SWISS-PROT database showed that 48% contain the YZX(S/T)K motif, 30% contain the Y(S/T)X(S/T)K motif, and 14% contain the Y(S/T)XZK motif where X is any residue and Z denotes residues other than serine (S) or threonine (T) (42) . This catalytic triad of residues has recently been extended to a tetrad as recent data have supported the concept that Asn111 is essential and highly conserved in most SDR forms (41, 43) . The regions likely to confer specificity are less well conserved, such as the potential substrate binding loop (between the ␤F strand and the ␣ G helix), and regions in the C-terminal segment (44, 45). The crystal structures of 27 members of the family have been reported, and their atomic coordinates have been deposited in the Protein Data Bank. All share a nearly superimposable protein-folding arrangement of ␣-helices and ␤-strands (␣ Ϫ ␤ Ϫ ␣ Ϫ ␤ ϫ 2) to form a Rossmann fold for cofactor binding (46), although this similarity is not present in the substratebinding pocket (47) . A comparison between the conformations of five SDR crystal structures (bacterial 3␣-, 20␤-HSD, human 17␤-HSD1, bacterial 7␣-HSD, mouse dihydropteridine reductase, and mouse lung carbonyl reductase) revealed that although there are only 11 fully conserved amino acid residues common to the five structures, the threedimensional conformation is highly conserved (48). The ␣-helix F interface of human 11␤-HSD1 has been modeled on the crystal structure of Streptomyces hydrogenans 20␤-HSD and has identified similar residues in type 1 that are important in the stabilization of the dimer of 20␤-HSD (49).
B. 11␤-HSD1 enzymology

Kinetic analyses.
From the pioneering studies of White and colleagues (50) and Monder and co-workers (51, 52) an 11␤-HSD was purified from rat liver, and an antiserum was raised against the protein and used to clone a rat cDNA although the cDNA sequence was subsequently updated in 2002 (53). This enzyme is microsomal (54), and activity is nicotinamideadenine dinucleotide phosphate (NADP) dependent; in the cell-free system it behaved mainly as a dehydrogenase, and no reductase activity was detected in the purified preparation. Subsequently, this enzyme was named 11␤-HSD1. Homogeneous enzyme gave rectilinear Eadie plots and MichaelisMenten (K m ) constants of 1.83 Ϯ 0.06 m for corticosterone and 17.3 Ϯ 2.24 m for cortisol. First-order rate constants were one order of magnitude higher for corticosterone than cortisol, but maximal velocities were similar (52). Subsequently, cDNAs and proteins were published for the human (55), mouse (56), squirrel monkey (57), sheep (58), rabbit (54), pig, cow, and guinea-pig (59, 60) 11␤-HSD1. Human liver 11␤-HSD1 was eventually purified in an active form and was postulated to exist as a dimer (61). The value of the K m determined for 11␤-HSD1 dehydrogenase activity is puzzling given that it is more than two orders of magnitude higher than the circulating level of free cortisol (1-100 nm). Maser et al. (61, 62 ) discovered an unusual kinetic mechanism of action of the human liver 11␤-HSD1. They determined that this isoform exhibits Michaelis-Menten kinetics with respect to cortisol but cooperative kinetics with cortisone. In this way, 11␤-HSD1 could operate at both nanomolar and micromolar substrate concentrations. However, using recombinant purified guinea pig and human proteins, no evidence for cooperative kinetics has been found (60). Mouse liver 11␤-HSD1 has been shown to accept nicotinamide-adenine dinucleotide (NAD) as well as NADP as cofactor (63, 64). Guinea pig liver 11␤-HSD1 has been shown to have equal affinity for cortisone and cortisol with apparent K m value in intact cells for both substrates being 3 m (59) and the pu- rified protein exhibiting a K m value for cortisone of 0.8 m (60). A summary of the published kinetic analyses of 11␤-HSD1 in differing species is given in Table 2 .
In original purification studies, 11␤-HSD1 in the liver was shown to be bidirectional, although, in contrast with its dehydrogenase activity, the reductase activity was unstable in vitro (52 ). These findings indicate a possible important role for 11␤-HSD1 dehydrogenase activity in normal physiology, with the relative contribution of the dehydrogenase and reductase activities being important in controlling the overall equilibrium of local glucocorticoid levels (81). In every case, however, when cells are disrupted or the enzyme purified, reductase activity is lost. This striking change in directionality between intact cells and homogenates seems to reflect the specific intracellular localization of 11␤-HSD1 within the lumen of the endoplasmic reticulum (ER), where neighboring enzymes may be powerful generators of the reduced cosubstrate NADP phosphate (NADPH). Indeed, studies using purified human enzyme have shown that the equilibrium constant for the E to F direction (defined as the concentration of products divided by concentration of reactants) is 0.03. Given that a figure of 1 would represent the exact equilibrium position, a value of 0.03 indicates a strong preference toward dehydrogenase (F to E) activity (82). Reductase activity can be regained from tissue homogenates and purified enzyme, upon inclusion of a NADPH regeneration system employing the cytosolic enzyme glucose-6-phosphate dehydrogenase (82, 83) . This suggests that reductase activity predominates in intact cells due to a high level of NADPH present within the ER lumen. Recently, it has been shown that the enzyme hexose-6-phosphate dehydrogenase (H6PDH) serves this crucial role in generating NADPH levels in the ER (84) (Fig. 1A ) (see Section VIII.B).
2. Protein structure. 11␤-HSDs can be separated from most other members of the SDR family due to the presence of one or more amino-terminal transmembrane domains. Other members of the SDR family that possess this secondary structure characteristic include some 17␤-HSD isozymes and follicular variant translocation protein isozymes. There is a high level of sequence homology between species (Fig. 2) , particularly within the cofactor-binding region (GASKGIG) and the catalytic site (YSASK). The 11␤-HSD1 protein has a single hydrophobic N-terminal extension preceding the cofactorbinding domain, suggesting that this region anchors the protein in microsomes. The precise topology of 11␤-HSD1 was demonstrated using 11␤-HSD1 constructs with attached FLAG epitopes at the N-and C-terminal regions (85) . The protein was shown to be intrinsic to the membrane of the ER, having a short five-amino acid region on the cytosolic side of the membrane, followed by a single transmembrane domain (Fig. 1B) and the majority of the enzyme residing in the lumen of the ER. Chimeric proteins, where the N-terminal regions from 11␤-HSD1 and 11␤-HSD2 were exchanged, led to inverted orientation within the ER. Both chimeric proteins were inactive (85) . Within the single N-terminal transmembrane region, the charge distribution of two positively charged lysine residues on the cytoplasmic side and two negatively charged glutamate residues suggests these are crucial residues in the orientation of 11␤-HSD1 in the ER membrane. Mutation analysis of Lys5 residue suggests that it is critical in the determination of 11␤-HSD1 topology and that its charge and specific side chain are both important (85) . The importance of the transmembrane domain upon 11␤-HSD1 activity has been studied, but with conflicting results. An N-terminally truncated variant of rat 11␤-HSD1 was expressed in COS cells and reported to be inactive (86, 87) . However, this construct encoded a protein that had lost more than just the transmembrane helix, and may, therefore, have lost vital parts of the enzymatic domain. In addition, these expression studies were performed in COS and Chinese hamster ovary cells, where the truncated protein would have been targeted (because of the lack of signal sequence) to the cytosol and not the ER. The lumen of the ER promotes the formation of disulfide bonds, and studies have indicated that there are important intrachain disulfide bonds within the 11␤-HSD1 protein (54). Extraction of the enzyme from the cells by sonication or the addition of fusion proteins to FIG. 1. A, Schematic representation of the interaction between 11␤-HSD1 and H6PDH, which provides NADPH as cofactor to permit reductase (cortisone to cortisol) activity. GT, Glucose-6-phosphate translocase; G6P, glucose-6-phosphate; 6PG, 6-phosphogluconolactonate. B, Three-dimensional structure and localization of 11␤-HSD1 within the lumen of the ER. the C terminus (88) possibly disrupting the conformation of the protein structure to the detriment of enzyme activity (47) could also account for the reported requirement of the Nterminal region for activity. However, analysis of 11␤-HSD1 constructs expressed in Escherichia coli demonstrated enzyme activity from an N-terminus-deleted construct, with activity levels even higher than those observed for the full-length 11␤-HSD1 construct (82). The importance of glycosylation upon 11␤-HSD1 activity has been variously reported. Examination of the 11␤-HSD1 peptide sequence revealed the presence of two potential Nlinked glycosylation sites in the cloned rat enzyme (asparagine-X-serine, residues 158 -160 and 203-205) consistent with the original description of the purified rat hepatic 11␤-HSD1 as a glycoprotein (52). Interestingly, studies in the vaccinia expression system showed that although partial inhibition of glycosylation decreased dehydrogenase activity by 50%, it did so without affecting reductase activity (83) . The relative importance of the two glycosylation sites was further investigated in a mutagenesis study in Chinese hamster ovary cells. Modification of the first site decreased dehydrogenase and reductase activities to 75 and 50% of the wild type, whereas mutation of the second site caused an almost complete abolition of both activities (89) . These findings show that in the rat, glycosylation of 11␤-HSD1 at N203 plays a major role, and at N158 a minor role in catalysis, and are consistent with the incomplete conservation of the corresponding residues between species. Conflicting studies on the human enzyme have also been reported. Within the human sequence, there are three putative glycosylation sites. The Asn-X-Ser sites are at positions 123-125, 162-164, and 207-209 of the protein. Human 11␤-HSD1 has been expressed in E. coli, where the biosynthesis of N-linked glycoproteins does not occur. This resulted in a recombinant protein that was completely devoid of enzyme activity (90) . The same group also investigated the effects of deglycosylation on human 11␤-HSD1 purified from liver and recombinant protein produced by the yeast Pichia pastoris (91) . Sitedirected mutagenesis of the three potential glycosylation sites yielded an inactive protein from yeast cells as assessed using metyrapone and metyrapol as the substrates. However, the enzyme purified from human liver, upon complete deglycosylation, remained fully active. In support of this finding, recent data conclusively show fully active nonglycosylated 11␤-HSD1 enzyme activity generated in E. coli, with kinetic properties for both dehydrogenase and reductase activities similar to those reported in mammalian systems (82). These data suggest that glycosylation is not required for correct protein folding or enzyme activity of the human 11␤-HSD1. Studies carried out on the rabbit enzyme, which, like the human homolog, contains three potential glycosylation sites, also suggest that glycosylation is not important for enzyme activity (54). Glycosylation of 11␤-HSD1, however, may still play a role in preventing protein aggregation, in addition to stabilizing the overall structure within the ER. The sequence of the guinea pig 11␤-HSD1 predicts only one N-glycosylation site (59), but the functional significance of this has not been investigated.
C. Substrate specificity and inhibitors of 11␤-HSD1
Numerous studies have been directed toward understanding the effects of various steroid moieties upon 11␤-HSD1 activity because any factors that inhibit metabolism of the 11␤-hydroxyl group will increase glucocorticoid potency. Most studies appear to have been performed with tissue extracts containing 11␤-HSD1 (9) . In essence, a substrate for 11␤-HSD1 possesses a flat A/B ring junction (5␣), with the 5␤ conformation disallowed; bulky groups on the ␣-surface inhibit binding, although the effect of ␣-halogens appears to be inductive rather than steric; an aromatic A ring is forbidden, and steroids with bulky groups at C-21 are not substrates. Data indicate the importance of the structural conformation of the A and B rings because modifications to these can confer specific inhibitory properties on some steroidal compounds (92) . C ring deoxysteroids, such as chenodeoxycholic acid (CDCA), can also be inhibitors for 11␤-HSD1 (93) . Many mammalian steroid dehydrogenases, including 11␤-HSD1, have been implicated in the detoxification of molecules in addition to roles in steroid metabolism (94 -96) . In addition to its important endocrinological involvement in glucocorticoid metabolism, 11␤-HSD1 mediates the phase I biotransformation of several carbonyl group-bearing foreign compounds, including xenobiotics (64), drugs (97, 98) , insecticides (99, 100) , and carcinogens (101, 102) . The reductive metabolism of xenobiotic compounds such as metyrapone, p-nitroacetophenone, and p-nitrobenzaldehyde (64) allows the formation of a hydroxyl group rendering the toxic substrate more hydrophilic and more likely to be conjugated by glucuronidation or sulfation facilitating excretion (103) . 11␤-HSD1 exhibits other protective roles with the inactivation of carcinogen, nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK), to its secondary metabolite, 4-methylnitrosamino-1-(3-pyridyl)-1-butanol (102), the metabolism of the antineoplastic agent, oracin, into its active metabolite, 11-dihydrooracin (97, 104) , the conversion of the nonsteroidal antiinflammatory prodrug, 5,5-dimethyl-3-(3-fluorphenyl)-4-(4-methysulfonyl)phenyl-2-(5H)-furanone-lactol, to its active lactone form (98) , and the detoxification of antiinsect agents (azole analogs of metyrapone) (100).
Inhibitors may have properties different from these. An exhaustive list of inhibitors has been compiled and includes steroids with C-21 and 2␣-methyl substituents (9) . The most commonly used inhibitor for in vitro studies and of clinical relevance are the licorice derivatives, glycyrrhizic acid, its hydrolytic product glycyrrhetinic acid, and the hemisuccinate derivative carbenoxolone (CBX). Glycyrrhetinic acid is a potent inhibitor of 11␤-HSD1 (both competitive and inhibiting 11␤-HSD1 mRNA levels) (105, 106) , and, in addition, inhibits 11␤-HSD2 with an inhibition constant (K i ) of 5-10 nm (73, 107).
Far fewer steroids have been shown to be inhibitors of 11-oxidoreduction, and obligatory functional groups have not been assigned. Reduction at C-20 eliminates inhibitory activity, but the specific configuration of side chains is not critical as androgens are also potent inhibitors (108) . Because the protein sequence of 11␤-HSD1 is not identical between species, subtle differences in protein conformation may lead to differences in substrate or inhibitor efficacy. Indeed, CBX displays little inhibition of ovine 11␤-HSD1 (109), although it inhibits both oxoreductase and dehydrogenase activities in human liver microsomes (93) . Clinical studies in subjects consuming glycyrrhetinic acid vs. CBX also suggest that CBX is an inhibitor of 11␤-HSD1 in vivo (110, 111) .
Prednisolone and prednisone are substrates for 11␤-HSD1 (112, 113) . 9␣-Fluorinated steroids, such as dexamethasone, are metabolized by 11␤-HSD2 (114) but may also be regenerated by 11␤-HSD1 (115) . The inhibitory effects of progesterone, glycyrrhetinic acid, and related compounds on 11␤-HSD1 have been reported, and 5␣ -and 5␤-adrenocorticoids inhibit 11␤-HSD1. Bile acids are potent inhibitors with lithocholic acid exerting the strongest effect (116) . In intact cells 11␣-hydroxyprogesterone is a more potent inhibitor of 11␤-HSD1 than glycyrrhetinic acid or 11␤-hydroxyprogesterone (117, 118) .
D. Selective inhibitors
To date, there are few inhibitor compounds reported to be specific for 11␤-HSD1. As mentioned earlier, a variety of bile acids have inhibitory effects on 11␤-HSD1 with lithocholic acid and CDCA reported as the most potent. However, only CDCA has been shown to be selective for 11␤-HSD1 oxoreductase and dehydrogenase activities (93) . The antidiabetic arylsulfonamidothiazole compounds have been shown to inhibit 11␤-HSD1 both in vivo and in vitro (119 -121). The diethylamide derivative was shown to inhibit human 11␤-HSD1 with an IC 50 of 52 nm, and an N-methylpiperazinamide form (BVT.2733: 3-chloro-2-methyl-N-{4-[2-(methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide) was shown to be specific for the mouse enzyme (IC 50 of 96 nm). In the hyperglycemic mouse strain KKA(y), the compound BVT.2733 lowered hepatic phosphoenol pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase mRNA, blood glucose, and serum insulin concentrations (121), raising the possibility that inhibition of 11␤-HSD1 might be used therapeutically to treat patients with insulin resistance (see Section VII.B.3).
IV. Molecular Biology of 11␤-HSD1
A. Cloning of 11␤-HSD1 cDNAs
The first mammalian 11␤-HSD to be cloned was a cDNA from rat liver, isolated using an antiserum raised against the purified protein (50 -52, 122). Initial analysis indicated an 861-bp open reading frame encoding a protein of 288 amino acids. Later, a cDNA library derived from human testis was probed using the rat 11␤-HSD cDNA, and clones were isolated (55). The human cDNA of approximately 1.4 kb in length predicted an open reading frame of 876 bp and a protein of 292 amino acids, which was 77% identical at the amino acid level to the rat enzyme (Fig. 2) . Subsequently, 11␤-HSD1 cDNAs have been cloned for a number of species including sheep (58), squirrel monkey (57), mouse (56), baboon (123), and guinea pig (59). Interestingly, and possibly unique among mammalian species, is the Australian koala, which appears to be devoid of 11␤-HSD1 activity in its liver. A study suggests that this may be due to the absence of a gene encoding 11␤-HSD1 activity homologous to that of other known species (124).
Alternate 11␤-HSD1 mRNA transcripts, as a result of differential promoter usage and alternate splicing mechanisms, have been demonstrated. In rat kidney, liver, and lung, a transcript initiated from an intron 1 promoter uses methionine 27 in exon 2 as a new start codon, maintaining the reading frame, and has been designated 11␤-HSD1B (86, 87) . However, expression of the truncated enzyme did not produce a soluble protein in its native form in cells (87) but was found to be active once released from the ER membrane when overexpressed in yeast (125). However, the precise role of this truncated form is not clear. Additional studies have also revealed a third putative 11␤-HSD1 congener in the sheep arising as the result of the deletion of exon 5 (126). The reading frame is maintained from exon 4 into exon 6, with the loss of 48 amino acids, which includes the catalytic domain (126). Again, no functional significance has been attributed to this transcriptional variant. The three proteins are now referred to as 11␤-HSD1A, 11␤-HSD1B, and 11␤-HSD1C, respectively. The message for 11␤-HSD1B is restricted to the kidney in the rat and parallels the developmental expression of 11␤-HSD1A mRNA (127). At present, there is no evidence that 11␤-HSD1C exhibits enzymatic activity toward glucocorticoids. However, the association of 11␤-HSD1A with carbonyl reductase activity in mouse liver suggests that it may act on substrates including xenobiotics (128, 129). Of note, an expressed sequence tag expressed in human pregnant uterus has been described that represents 11␤-HSD1C; however, the significance and validity of this finding remains unclear (130).
B. Human HSD11B1 gene
Hybridization of the human 11␤-HSD1 cDNA to a humanhamster hybrid panel localized the single HSD11 gene to chromosome 1 (subsequently refined to chromosome 1q32. . Genomic clones of HSD11 were isolated from a chromosome 1-specific library, again using the cDNA as a probe (55). The human gene has been designated HSD11B1 and consists of six exons (182, 130, 111, 185, 143 , and 617 bp, respectively) and five introns (776, 767, 120, 25,300, and 1,700 bp, respectively) (Fig. 3) .
Originally, the HSD11B1 gene was thought to be approximately 9 kb in size; however, the isolation and analysis of a PAC clone containing the entire human HSD11B1 gene revealed that intron 4 spans approximately 25 kb, expanding the gene size to 30 kb (131). Primer extension analysis using human liver RNA indicated that transcription initiates 93 bp upstream from the start of translation, yielding a 5Ј-untranslated region similar in length to that of rat 11␤-HSD1 mRNA. There is no TATA box in the 5Ј-flanking region, but there is a consensus CAAT box 76 bp upstream of the start of transcription (55).
To date, there are few reports describing polymorphism in and around the HSD11B1 locus. A scan of the GenBank single-nucleotide polymorphism (SNP) database (db SNP at http://www.ncbi.nim.nih.gov/SNP/) reveals a number of documented sequence variations detected primarily through human genome-sequencing projects (and our unpublished observations). All but one polymorphism is located in noncoding regions of the gene; 31 SNPs are within intron 4, one SNP is located in the 3Ј-untranslated region, and seven SNPs are located within 2 kb of the mRNA transcript (three in 5Ј-regions of the gene and four in 3Ј-gene regions). An adenine insertion has been detected in intron 3. The coding region SNP is a synonymous C to T change in exon 5 that has no effect upon the encoded amino acid (Ser204Ser). Also, two polymorphic CA repeat microsatellites located at opposite ends of the 25-kb intron 4 of the HSD11B1 gene have been isolated (124). A deletion of 11 bp in intron 1 [position 441-451 of GenBank accession no. M76661 (Exon 1)] was detected in one study. This polymorphism does not alter splicing and does not affect donor or acceptor splice sites (130). Analysis of the polymorphism showed that the 11 bases appear to belong to a tandem repeat consisting of two contiguous repetitions of the same 11 nucleotides, and thus could easily be deleted due to mispairing during replication.
Recently, two further polymorphisms have been identified within intron 3 of HSD11B1 that are in complete linkage disequilibrium: an A insertion (83557), and 40 bp downstream a T to G substitution (83597). Functional analyses showed that these polymorphisms reduce transcriptional activity of HSD11B1 by 2.5-fold in luciferase reporter assays, suggesting that this region of the gene acts as an intronic enhancer of HSD11B1 expression (84) .
The rat 11␤-HSD1 promoter has been cloned from genomic DNA (132). An initial study utilizing this sequence demonstrated a single major promoter in the rat liver, but two further promoters are used in the kidney (132). Analysis of the promoter revealed the presence of a CCAAT sequence at Ϫ73 to Ϫ69 (transcription start site is ϩ1), and the lack of a TATA box. Several putative transcription factor-binding sites were identified including several glucocorticoid response element consensus half-sites, hepatocyte nuclear factor 1, hepatocyte nuclear factor 3, and CAAT/enhancer binding proteins (C/EBP) sites. Also a (CT)26 microsatellite is present at Ϫ462 (133).
Recent studies upon the rat 11␤-HSD1 promoter showed that it is predominantly regulated by the C/EBP family of transcription factors, mainly C/EBP␣. C/EBP␣ coordinately regulates a series of genes concerned with the metabolism of fuels (134), and C/EBP␣ is regulated by glucocorticoids in a tissue-specific manner (135). In liver, basal C/EBP␣ levels are high, ensuring high levels of 11␤-HSD1 transcription, and hence high glucocorticoid levels (80). The 11␤-HSD1 promoter exhibits an unusually large number of these sites, having at least 10, with most genes containing two or three sites. Williams et al. (133) developed a series of reporter plasmids containing increasing sized promoter regions (from Ϫ88 to Ϫ3.5 kb/ϩ49), transfected into HepG2 cells (human hepatoma cell line). These experiments identified a repressor element between Ϫ812 and Ϫ754. C/EBP␣ inducibility of the 11␤-HSD1 promoter was most prominent between Ϫ579 and Ϫ88.
DNase 1 protection analysis identified 11 sites of nuclear protein interaction with the 11␤-HSD1 promoter, and 10 of these can be occupied by C/EBP-related proteins (133). Two of these regions, FP1 and FP2, span the transcription start site between Ϫ88 and ϩ76. Mutation analysis of four footprinted sites proximal to the transcription start site FP1, FP2, FP3, and FP4 showed that they are required for full C/EBP␣ inducibility and basal transcription. Mutation of FP2 actually decreased basal transcription levels, suggesting that C/EBP may act here as an initiator (Inr)-binding protein. EMSA analysis confirmed that C/EBP␣ binds to at least two of the footprinted sites (133). Analysis of 11␤-HSD1 liver RNA expression in C/EBP␣ knockout mice confirmed these findings: 11␤-HSD1 was dramatically reduced in these mice compared with wild-type littermates (136).
Similar analysis of the related transcription factor, C/EBP␤, showed it to be a weak activator of 11␤-HSD1 transcription, and C/EBP␤ knockout mice (137) show increased hepatic 11␤-HSD1 mRNA expression (133).
The importance of C/EBP␣ in the regulation of 11␤-HSD1 transcription has been shown only for the rat promoter thus far, and it will be interesting to note whether this translates to the human promoter sequence and whether other transcription factors play a similarly important role.
The analysis of the HSD11B1 gene in patients with CRD and the application of the polymorphisms in linkage and association studies are detailed in Sections VIII and IX.
C. Recombinant models of 11␤-HSD1
To determine the role of 11␤-HSD1 in vivo, transgenic mice with a null HSD11B1 gene have been generated by the replacement of the genomic region containing exons 3 and 4 with a neomycin-resistance cassette via homologous recombination in mouse 129 embryonic stem cells (138). The resulting knockout mice were fertile, had regular litter size with pups of normal birth weight, and postnatal development with normal morphological appearance. There was no deviation from Mendelian inheritance of alleles, and therefore no embryonic lethality associated with this knockout was assumed. No mRNA from 11␤-HSD1 homozygous mutant mice, and approximately 50% mRNA from heterozygous mice was detected by Northern analysis compared with wild type, confirming the true ablation of this gene. In homozygous mutant mice hepatic 11␤-HSD activity was less than 5% of wild type. Wild-type and knockout mice were adrenalectomized and implanted with 11-dehydrocorticosterone pellets. Wild-type mice readily converted 11-dehydrocorticosterone to corticosterone, whereas corticosterone levels in knockout mice remained undetectable, demonstrating that 11␤-HSD1 is the only 11-oxoreductase (at least in the mouse) able to generate active glucocorticoid from inert 11-ketosteroids. 11␤-HSD Ϫ/Ϫ mice also displayed adrenal hyperplasia due to reduced negative feedback on the HPA axis causing increased ACTH-stimulated corticosterone secretion. The expression and activity of the 11␤-HSD2 enzyme appeared to be unaffected in this model, suggesting no compensatory mechanisms.
An important experiment, which tested the hypothesis that increased 11␤-HSD1 activity within adipose tissue may be implicated in obesity and the metabolic syndrome, was the creation of transgenic mice overexpressing the enzyme (139). This was achieved through the fusion of 5.4 kb of the aP2 promoter/enhancer, which is an adipocyte-specific promoter, and a 1.6-kb fragment of rat 11␤-HSD1 cDNA, followed by an SV40 consensus polyadenylation signal. This construct was microinjected into the pronucleus of fertilized FVB mouse eggs. Successful targeting of transgene expression was determined by RNase protection assay using a probe able to differentiate between transgene-derived and endogenous 11␤-HSD1 mRNA from various adipose tissues and showed relative equivalence in expression in adipose tissue from sc, epididymal, mesenteric, and interscapular brown adipose tissue depots. The transgene was not expressed in nonadipose tissue such as brain and liver of transgenic mice. All mice studies were performed on inbred strains of male FVB mice in which transgene mRNA expression was increased 7-fold compared with endogenous mRNA. 11␤-HSD1 enzyme activity was increased almost 3-fold in adipose tissue, comparable to ob/ob mice or that seen in obese humans (140), demonstrating that the extent of transgenic amplification of 11␤-HSD1 activity is physiologically relevant. Transgenic mice under nonstressed conditions had similar serum corticosterone concentrations as controls, whereas concentrations in adipose tissue were elevated up to 30% higher compared with wild-type mice, reflecting local increased activation of glucocorticoid via 11␤-HSD1.
The detailed phenotype of these animals is discussed in Section VII. However, to further define the role of 11␤-HSD1 upon homeostasis, it may be necessary to develop more refined recombinant mouse models. The use of Cre-LoxP technology in the generation of a conditional HSD11B1 allele, whereby particular gene promoters of Cre recombinase can ablate gene function in a spatial and temporal manner, would provide information on the relative contributions of specific tissues such as liver and adipose to the global effects of 11␤-HSD1 enzyme activity on murine physiology.
V. Localization and Ontogeny of 11␤-HSD1
A. Localization
A variety of studies have examined expression using different methodologies that include immunohistochemistry, Western blotting, PCR, and specific enzyme assays. Table 3 provides a comprehensive list of the tissue-specific distribution of 11␤-HSD1 in different species from which it can be seen that 11␤-HSD1 is expressed in many tissues throughout the body. Expression often occurs in what have traditionally been regarded as glucocorticoid target tissues. Highest levels of expression are seen in the liver, gonad, adipose tissue, and brain, and these are discussed in more detail in Section VII.
B. Ontogeny and sexual dimorphic expression
In contrast to 11␤-HSD2, the ontogeny of 11␤-HSD1 is less well characterized, but it has been most extensively studied in rodents. In rat liver, 11␤-HSD1 activity can be detected during gestation (141). Dehydrogenase activity predominates and increases with advancing gestation into adult life (142, 143). The patterns of expression in the rat lung are similar to those seen in the liver, although levels of activity are lower (141, 142).
Within the rat fetal brain, 11␤-HSD1 is undetectable until late gestation. Expression then begins to appear in the hippocampus, precerebellar area, and medulla. Subsequently, a more generalized increase in expression occurs, and at birth expression is highest in the thalamus, neocortex, hypothalamus, pituitary, periaqueductal gray area, spinal cord, and hippocampus (143). However, although expression has been detected using in situ hybridization, there is little detectable enzyme activity (143). In contrast, in primary cultures of rat fetal hippocampal neurons, significant amounts of 11␤-HSD1 reductase activity can be detected (72). Within the postnatal rat cortex and hippocampus, 11␤-HSD1 activity decreases until postnatal d 10 and then increases. Conversely, in the cerebellum a peak of activity is reached by d 10 and then gradually falls until adult levels are achieved (d 15) (144).
In the mouse, 11␤-HSD1 expression is undetectable but rises dramatically after birth until sexual maturity, after which it declines (145).
Ontological expression has also been studied in sheep. In sheep liver 11␤-HSD1 expression is present by midgestation. Levels remain constant until immediately before birth when they increase more than 2-fold. Reductase activity always exceeds dehydrogenase activity (146). In the pars distalis of the sheep pituitary, 11␤-HSD1 expression can be detected by midgestation and, although levels do not change in late gestation, they increase dramatically after birth (147). Both reductase and dehydrogenase activities are present, although dehydrogenase activity predominates. However, in a further study, levels of activity in liver and pituitary were similar in tissues from late gestational fetuses and adults (148). In the pars intermedia, 11␤-HSD1 is only detectable at term, and levels do not change after birth (147). In the ovine placenta 11␤-HSD1 immunoreactivity is observed in the fetal trophoblast cells. Dehydrogenase activity exceeds reductase, and activity decreases in late gestation (149).
Studies in humans are very limited. In fetal lung tissue homogenates, small amounts of dehydrogenase activity have been detected. In the neonatal and infant period, reductase activity is present although this is lost on progression through childhood (150). The significance of these results and, in particular, the source of dehydrogenase activity are uncertain, being published before the elucidation of the two 11␤-HSD isozymes. However, in primary cultures from explants of midgestation human fetal lung, both reductase and dehydrogenase activity are observed (151), suggesting the presence of 11␤-HSD1. In other tissues, however, 11␤-HSD1 could not be identified at least at midgestation (152).
The activity of 11␤-HSD1 in childhood is not well characterized. Cortisone acetate therapy in neonates with congenital adrenal hyperplasia is ineffective up to 2 months of age, reflecting a lack of 11␤-HSD1 reductase (principally hepatic) activity (153). In children aged 4 or 5 yr, activity, as measured by urinary corticosteroid metabolites, is similar in boys and girls (154). In boys, activity remains relatively constant up to, and during, puberty. However, in girls activity decreases around the time of puberty (154), and it is possible that it is at this time point that the well-described sexually dimorphic pattern of activity is obtained. In most studies in both elderly normal individuals (155) and in GH-deficient, hypopituitary patients (28), 11␤-HSD1 activity is higher in men. In rats, although not in mice (56), a similar sexual dimorphic pattern is observed (156). The explanation for this difference in rats is believed to lie in patterns of GH secretion. Hypophysectomized male rats given a continuous GH infusion (as observed in female rats), suppress 11␤-HSD1 in the liver to levels observed in females (156, 157). The explanation in humans is not clear although it seems unlikely to involve regulation by estrogen as differences persist into the postmenopausal period (155). However, one additional study (158) , although demonstrating sex differences in A-ring reductase activity, has failed to confirm this relationship.
VI. Regulation of 11␤-HSD1 Expression
It should be appreciated that most of the regulation studies performed particularly on rodent tissues before the characterization of the two principal 11␤-HSD isozymes in 1994/ 1995 (and some which have been performed since that time) have failed to dissect out specific effects on either 11␤-HSD1 or 11␤-HSD2. Table 4 summarizes the studies that have analyzed the regulation of 11␤-HSD1 and details the tissues and species studied. To summarize, glucocorticoids, C/EBP, peroxisome proliferator-activated receptor-␥ agonists, and some proinflammatory cytokines (TNF␣, IL-1␤) increase 11␤-HSD1 expression, whereas GH (acting via IGF-I) and liver X receptor agonists inhibit expression. The effect of other factors, including sex steroids, insulin, and thyroid hormone, vary from tissue to tissue and between species (Table 4) . IFN, Interferon; EGF, epidermal growth factor; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; PKA, protein kinase A; PKC, protein kinase C; PMSG, pregnant mare serum gonadotropin; PPAR, peroxisome proliferator-activated receptor; hCG, human chorionic gonadotropin; 1, increase; 2, decrease; 4, unchanged.
a Metyrapone and its analogs are known to act as substrates for 11␤-HSD1 (100). 
VII. Role of 11␤-HSD1 in Normal Physiology and Pathophysiology in Peripheral Tissues
A. Kidney, colon, and skin
The first 11␤-HSD isozyme to be characterized in the kidney was 11␤-HSD1. In situ hybridization studies did report the presence of 11␤-HSD1 mRNA within rat distal nephron (159, 160) , and immunoreactivity was observed only in renal proximal tubules in the cortex and to interstitial cells within the medulla; no immunoreactivity was observed over the aldosterone target cells, distal tubules, and collecting ducts (161) (162) (163) . In contrast to the rodent, little, if any, 11␤-HSD1 is expressed in human or sheep kidney and, in humans, expression is confined to the renal medulla. This was one impetus to the cloning and characterization of the highaffinity, NAD-dependent 11␤-HSD2 isozyme (107) that, expressed in distal renal epithelial cells, serves to protect the MR from cortisol excess (1).
11␤-HSD1 is expressed in cultured rat glomerular mesangial cells where it is up-regulated by IL-1␤ and TNF␣ and may modulate the antiinflammatory effects of glucocorticoids at this site (164) . Renal 11␤-HSD1 is down-regulated in a heritable model of polycystic kidney disease, the cpk mouse (165) . The relevance of these observations to human renal physiology or pathophysiology is uncertain.
11␤-HSD activity was demonstrated in the human colon in the early 1980s (166); expression is confined to nonepithelial cells within the lamina propria of the rat colonic mucosa (167) . The function of the 11␤-HSD1 enzyme at this site is unknown. A nuclear receptor with a high affinity for 11-dehydrocorticosterone has been postulated to be present within the rat colon (168) , and it is possible that 11␤-HSD activity may modulate ligand exposure to such a receptor.
In the skin, 11␤-HSD1 is expressed in the epidermis, and whereas the directional activity of the enzyme at this site has not been established, the potency of topically applied hydrocortisone (as assessed by the skin vasoconstrictor assay) can be increased by glycyrrhetinic acid administration (169) . In vitro, reductase activity predominates in human skin fibroblasts, and this is increased by glucocorticoids and inhibited by insulin (68).
B. Liver and adipose tissue
1. Liver. 11␤-HSD1 is expressed in the rodent and human liver, and, in man, the activity of this enzyme confers biological potency upon orally administered cortisone. In the human liver, 11␤-HSD1 is localized centripetally with maximum expression around the central vein (170) . Whereas the reductase activity of 11␤-HSD1 appears to be unstable in homogenates in vitro, primary cultures of rat and human hepatocytes indicate exclusive 11-oxoreductase activity (67, 171). In the intact perfused rat liver, activity is predominantly, although not exclusively, reductase. Interestingly, simultaneous perfusion with CBX fails to inhibit activity. However, 7 d of pretreatment with oral CBX decreased reductase activity significantly (172) .
In rats (157, 172-174), but not mice (56), 11␤-HSD1 expression is 18-fold higher in males compared with females (157), an observation that can be explained by the sexual dimorphic pattern of GH secretion (156) (see Section V.B). Estrogens and insulin reduce 11␤-HSD1 expression in the rodent liver (174) , but a series of growth factors including TGF␤, basic fibroblast growth factor, epidermal growth factor, and hepatocyte growth factor are without effect (171) . In the rat 2S FAZA hepatoma cell line, reductase activity is also inhibited by insulin and IGF-I and stimulated by dexamethasone (175) . The promoter region of the rat 11␤-HSD1 gene has been cloned and is positively regulated by C/EBP␣ (133) and, to a lesser extent, by C/EBP␤. T 4 appears to regulate hepatic 11␤-HSD1 mRNA and activity levels (176), although varying effects have been reported in different tissues in rodents and man (171, 176, 177) . In man, hyperthyroidism moves the set point of F to E conversion toward E, and studies suggest that this requires a functional thyroid hormone receptor rather than being due to a direct effect of thyroid hormone per se on 11␤-HSD1 (178) .
In sheep liver microsomes, metyrapone inhibits 11␤-HSD1 reductase activity (179) , and this may provide a further explanation for its inhibitory effects on adrenal steroidogenesis.
Chronic liver disease is associated with deranged cortisol metabolism. Urinary steroid profiles performed on patients with both alcoholic and nonalcoholic chronic liver disease indicate a marked increase in the THFϩallo-THF/THE ratio, suggesting either a reduction in renal 11 ␤-HSD2 or an increase in hepatic 11 ␤-HSD1 oxoreductase activity (180) . However, in rats with cirrhosis, both hepatic 11 ␤ -HSD1 and renal 11 ␤-HSD2 were reduced, and this could be explained by the inhibitory action of bile salts (181).
Adipose tissue.
Significant expression of 11␤-HSD1, but not 11␤-HSD2, has been found in human adipose tissue (69, 182). Activity is predominantly reductase in nature and is induced by glucocorticoids and proinflammatory cytokines (183) (184) (185) . Activity and expression are significantly higher in omental compared with sc preadipocytes (69, 70). The enzyme is induced upon adipocyte differentiation in human adipose tissue cultures (stromal cells to adipocytes). In stromal cell cultures, this is more related to a "switch" in enzyme set point from dehydrogenase (stromal cells) to reductase (adipocytes) without any significant change in 11␤-HSD1 mRNA levels (78). This may be explained upon induction of H6PDH across differentiation (84) (see Section VIII). With the known effect of glucocorticoids on adipose tissue function and distribution, it has been postulated that the enhanced conversion of E to F within omental adipose tissue plays an important role in the pathogenesis of central obesity. Cortisol is essential for adipocyte differentiation (186) , and the autocrine generation of cortisol through the action of 11␤-HSD1 is able to regulate this process. Both cortisol and cortisone promote differentiation. Inhibition of 11␤-HSD1 prevents cortisone-mediated adipocyte differentiation by blocking the activation of cortisone to cortisol (Fig. 4) (70) . In addition, increasing reductase activity during adipocyte differentiation may ensure delivery of cortisol to permit continued differentiation (78). Mice overexpressing 11␤-HSD1 under the aP2 promoter have enhanced adipocyte differentiation (as measured by increased fat cell size) as a consequence of increased adipose tissue corticosteroid concentrations (139) (see Section VII.B.3.b. and Fig 5) . In general, glucocorticoids inhibit cellular proliferation by inducing cell cycle arrest at the G1 phase (187, 188) , and the prereceptor modulation of cortisol metabolism has a dramatic effect upon cell proliferation rate (189) . In both rat and human preadipocytes, glucocorticoids exert an antiproliferative effect (190) , and inhibition of 11␤-HSD1 was shown to ameliorate the antiproliferative action of cortisone (Fig. 4) (191) . Additionally, in adipose stromal cells, 11␤-HSD1 has also been shown to regulate the glucocorticoid induction of aromatase activity (192) .
In the absence of a human transformed adipocyte cell line, murine 3T3-L1 and 3T3-F442A adipocyte cell lines have been studied. 11␤-HSD1-mediated reductase activity and expression were shown to increase with differentiation in 3T3-L1 and 3T3-F442A mouse cell lines, reaching maximum 6 -8 d after confluence (193) . Microarray data showed increased (5-fold or more) expression of 11␤-HSD1 in 3T3L1 cells during differentiation across a 7-d period (194) .
The expression of 11␤-HSD1 in 3T3-F442A cells has been shown to be regulated by dexamethasone and insulin in line with glycerol 3-phosphate dehydrogenase expression (193) . Peroxisome proliferator-activated receptor-␥ agonists indirectly inhibit 11␤-HSD1 mRNA expression in 3T3-L1 cells (195) . Similarly, agonists for liver X receptor-␣ and -␤, the nuclear oxysterol receptors involved in lipid metabolic regulation, decreased 11␤-HSD1 mRNA expression and activity (cortisone to cortisol), a process that requires ongoing protein synthesis (196) .
3. Insulin sensitivity. The pathological effects of circulating cortisol excess are exemplified in patients with Cushing's syndrome who may develop glucose intolerance, decreased insulin sensitivity, and reversible central obesity. Largely based on these observations, there is currently great interest in 11␤-HSD1 and its putative role in regulating insulin sensitivity. This can occur at the level of the liver (hepatic gluconeogenesis), adipose tissue (central obesity), or muscle. a. Hepatic gluconeogenesis. As discussed above, 11␤-HSD1 is highly expressed in both rodent and human hepatocytes; in intact hepatocytes (67) and in the perfused intact rat liver (172) , activity is almost exclusively reductase. Glucocorticoids are potent regulators of many of the key enzymes involved in hepatic gluconeogenesis including PEPCK, the rate-limiting step in hepatic gluconeogenesis (197) . Estradiol treatment to Wistar rats decreases PEPCK expression, an effect that is dependent upon reduced 11␤-HSD1 expression and the resulting decrease in hepatic corticosterone generation (173, 174, 198) . The 11␤-HSD1 knockout mouse does not display fasting hypoglycemia in the basal state; however, when fed a high-fat diet, fasting glucose levels are significantly lower than wild-type controls (138). Furthermore, although at baseline, hepatic expression of glucose-6-phosphatase and PEPCK did not differ from controls, they lack the characteristic induction upon starvation (138). Recently, 
highly selective inhibitors of 11␤-HSD1 have been developed, and in rodents administration for 7 d significantly decreases both hepatic glucose 6-phosphatase and PEPCK expression (119) . In addition, in the fasting state as well as during oral glucose tolerance testing, glucose and insulin concentrations are decreased in mouse models of type 2 diabetes mellitus (121). These in vitro and rodent studies are highly suggestive of a modulatory role for 11␤-HSD1 in the control of hepatic gluconeogenesis. These observations are borne out in clinical studies. CBX treatment in healthy men decreases hepatic glucose production (199) . In addition, during a hyperinsulinemic, hyperglucagonemic, normoglycemic clamp, glucose production rates decrease after treatment with CBX in patients with type 2 diabetes mellitus. However, this was principally due to reduced glycogenolysis with no effect on hepatic gluconeogenesis (200) .
Although there is considerable evidence that alterations in hepatic glucocorticoid concentrations can impact upon hepatic glucose flux, observational clinical studies in states of impaired glucose tolerance have, in almost all cases, demonstrated decreased hepatic 11␤-HSD1 reductase activity as measured by cortisol generation profiles after an oral dose of cortisone acetate (140, [201] [202] [203] and urinary F/E metabolite ratios (140, 203). Furthermore, leptin-deficient and leptinresistant models of obesity display decreased hepatic 11␤-HSD1 expression (204) . However, analysis of urinary corticosteroid metabolites has failed to show differences between patients with type 2 diabetes mellitus and healthy controls (205) , although cortisol generation from oral cortisone appears to be impaired (201) . It is plausible that decreased hepatic cortisol concentrations, resulting from decreased 11␤-HSD1 expression, represent a physiological compensatory mechanism to decrease fasting hyperglycemia and to improve insulin sensitivity.
Transgenic mice overexpressing hepatic 11␤-HSD1 have been developed. These animals appear to have elevated insulin levels after a glucose load as well as dyslipidemia and hypertension, but more detailed data with respect to hepatic glucose flux in these animals are not yet available (206) .
b. Central obesity. The description of 11␤-HSD1 expression within adipose tissue and the suggestion that it may lead to central obesity-"Cushing's disease of the omentum" (69)-have stimulated a critical appraisal of the role of 11␤-HSD1 in models of both rodent obesity and human obesity.
i. 11␤-HSD1 and rodent models of obesity. Whereas there are clear differences between rodent and human obesity, these studies have enhanced our understanding of the role of tissue-specific cortisol metabolism in the pathogenesis of visceral obesity. In the obese Zucker rat, adipose tissuespecific 11␤-HSD1 expression is increased and hepatic expression is decreased (207) . The mechanism for this dysregulation is not known. It is unlikely that insulin mediates this response, and insulin sensitizers, the thiazolidinediones, fail to correct this dysregulation in obese rats (208) . Tissuespecific regulation by growth factors and cytokines may be important (183) . These animals also have decreased 11␤-HSD1 expression within hippocampal neurons, and this may be important in the abnormalities that are present in the HPA axis in obesity (209) . Recently, 11␤-HSD1 expression has been examined in other obesity-prone rodent models. Hepatic expression inversely correlates with markers of obesity in leptin-deficient and leptin-resistant models (204) . In the leptin-deficient, but not the leptin-resistant, model this can be reversed by recombinant leptin therapy (204) . Adipose tissue 11␤-HSD1 expression decreases with high-fat dietary feeding in other obesity-prone models (210) . This down-regulation in liver and adipose tissue would appear to conflict with some of the human data described below. It is possible that this represents a compensatory mechanism in obesity to decrease tissue-specific corticosterone generation in an attempt to increase insulin sensitivity.
The 11␤-HSD1 knockout mouse does not display a characteristic adipose tissue phenotype (138). It does, however, resist high-fat diet-induced obesity despite increasing food intake, and, in addition, insulin sensitivity is enhanced (211) . The lack of phenotype may be explained by the fact that expression is lost at both an adipocyte and preadipocyte level. Within each cellular compartment, 11␤-HSD1 is likely to have distinct roles limiting proliferation in preadipocytes (191) and promoting differentiation and lipid accumulation in mature adipocytes (70). Evidence to support this comes from the development of the transgenic mouse overexpressing 11␤-HSD1 under the adipocyte-specific aP2 promoter (139). These mice develop a centrally obese phenotype as a consequence of elevated local glucocorticoid levels (Fig. 5) . The predisposition for central obesity probably relates to the increased expression of GR in omental rather than sc fat. Importantly, however, because the transgene was targeted to already differentiating cells (aP2 is only expressed in adipocytes committed to differentiation) it will have had little effect on preadipocytes, and this is reflected in the fact that increases in adipose tissue mass were a consequence only of increased cell size and not number. In addition, these animals also develop hypertension with elevated circulating levels of angiotensinogen, angiotensin II, and aldosterone (212) . This is an elegant model of visceral obesity and the metabolic syndrome, and its importance lies in demonstrating the impact of tissue-specific cortisol metabolism. However, increased adipose tissue corticosteroid levels have not been demonstrated in human obesity.
ii. Human obesity. The role of cortisol metabolism and, in particular, 11␤-HSD1 in the pathogenesis of visceral obesity in man is an area of much scientific, clinical, and pharmaceutical interest. The global epidemic of obesity and its associated morbidity and mortality have hastened the need to determine its pathogenesis and to develop effective therapeutic strategies. The pathological effects of glucocorticoid excess are exemplified in patients with Cushing's syndrome. Patients with visceral obesity and the metabolic syndrome share many of these features, although circulating cortisol levels in these patients are not elevated (213, 214) . 11␤-HSD1 is highly expressed in human adipose tissue (69, 170, 214). In whole adipose tissue, levels of expression are similar between omental and sc depots (191) . However, in preadipocytes, the fibroblast-like precursors of mature adipocytes, expression is higher in omental cells (69, 191, 215) . Adipose tissue-specific expression of 11␤-HSD1 in human obesity remains a controversial area. The parallels with Cushing's syndrome have led to the hypothesis that adipose tissuespecific overexpression and therefore increased adipose tissue cortisol concentrations through enhanced reductase activity underpin the pathogenesis of visceral obesity. Until recently, few clinical studies had addressed this question.
Global assessments of 11␤-HSD1 activity have been undertaken in several clinical studies and have used two principal methods. Generation of cortisol from an oral dose of cortisone acetate is believed to largely reflect hepatic 11␤-HSD1 activity. In obese patients this activation is impaired (140, 202, 203) . The urinary THFϩallo-THF:THE ratio, in the setting of a normal UFF and UFE excretion, is also believed to reflect global 11␤-HSD1 activity (26) . Results have been more variable in comparison with the cortisol generation profile. Some studies have described decreased ratios consistent with decreased 11␤-HSD1 reductase activity with increasing body mass index (BMI) in simple obesity (140, 203) . Other studies have failed to show this relationship (213, 216 -218) and, indeed, positive correlations have also been described (202, 219, 220) . The explanation for this discrepancy is not clear. However, in all cases cortisol generation after an oral dose of cortisone is clearly reduced in simple obesity. The sexual dimorphic expression of 11␤-HSD1 in the rodent has been discussed in Section V.B. As determined from a reduced THFϩallo-THF/THE, but unchanged UFF/UFE ratio, human studies also suggest a reduction in 11␤-HSD1 oxoreductase activity in females compared with males (28, 155) , and this may be explained on differing patterns of fat distribution.
In adipose tissue, Weidenfeld et al. (221) obtained sc adipose tissue biopsies from lean and obese individuals and were unable to detect differences in 11␤-HSD1 dehydrogenase activity (the preferred direction when 11␤-HSD1 is disrupted from its normal cellular localization) in tissue homogenates. There were, however, only three patients in each group (221) . Arteriovenous gradients of cortisol and cortisone across sc abdominal fat have also been used to assess 11␤-HSD1 activity, and cortisone clearance correlates with total body fat (222) . More recently, several clinical studies have examined 11␤-HSD1 activity in sc abdominal adipose tissue from obese men and women including a population of obese Pima Indians (140, 202, 223). Dehydrogenase activity in adipose tissue homogenates in these studies significantly correlated with indices of obesity. In an additional study using in situ hybridization, mRNA expression in sc adipocytes (but not preadipocytes) was highest in the most obese patients (215) . In our own studies, we were unable to detect differences in mRNA expression in whole adipose tissue between lean and obese individuals using real-time RT-PCR. Furthermore, in cultured preadipocytes, 11␤-HSD1 reductase activity decreased with increasing BMI (191) . The apparent discrepancies in some of these clinical data may be due to the fact that all of these studies have had relatively small subject numbers and that they have all used different techniques and assays to determine 11␤-HSD1 activity. Whereas 11␤-HSD1 activity correlates well with mRNA expression in some of these studies, it does not correlate with adipose tissue cortisol concentrations (224) . Therefore, the hypothesis that human obesity occurs as a consequence of adipose tissue-specific overexpression of 11␤-HSD1 and hence increased tissue-specific cortisol concentrations is yet to be confirmed. Our inclination is the converse-that 11␤-HSD1 expression in liver is already reduced in obesity and serves as an important protective mechanism to protect against the ongoing deleterious metabolic effects of obesity.
c. Muscle. 11␤-HSD1 is also expressed in skeletal muscle (225) . The role of tissue-specific cortisol metabolism within muscle and its impact upon insulin sensitivity have not been extensively studied. However, in a single study, levels of expression within human skeletal myoblasts correlated with measures of insulin resistance, BMI, and blood pressure (225) .
d. GH deficiency (GHD).
Adult patients with endogenous GHD are known to have a series of metabolic defects including insulin resistance and obesity. Studies in hypopituitary patients commencing GH therapy show a reduction in the THFϩallo-THF/THE ratio but no alteration in the UFF/ UFE ratio, indicative of a decrease in 11␤-HSD1 reductase activity (226) . The same finding was confirmed in elderly GH-deficient subjects (29) . In untreated GH-deficient hypopituitary subjects, urinary THFϩallo-THF/THE ratios are increased by about 50% from baseline. The opposite is seen in untreated acromegalics (227) . These clinical studies are endorsed by studies in vivo that also indicate reduction of hepatic 11␤-HSD1 expression in rats treated with GH (156, 228, 229). However, subsequent in vitro analyses revealed that GH has no direct effect upon 11␤-HSD1 activity, but that the GH effects are mediated via IGF-I; IGF-I inhibits 11␤-HSD1 activity (175, 227) . This is supported by the observation that pegvisomant, a GH antagonist that increases endogenous GH but effectively blocks GH signal transduction and lowers IGF-I levels, reverses the reduction in the THFϩallo-THF/THE ratio seen in untreated acromegaly (30) . GH therefore, acting via IGF-I, increases the metabolic clearance rate of cortisol by inhibiting 11␤-HSD1. Clinically, care should be taken to ensure adequate cortisol replacement in GHD patients commencing GH replacement therapy. Equally, there are many similarities between Cushing's syndrome and GHD (central obesity, osteopenia, insulin resistance, premature cardiovascular mortality), and it is exciting to speculate that the phenotype of GHD may, in part, relate to its modulation of the tissue-specific actions of cortisol.
C. Fetoplacental tissues
In contrast to adulthood where the ratio of circulating F/E is 7:1, the ratio in umbilical arterial and venous blood is approximately 1:1. This relative increase in cortisone levels reflects the intense and extensive expression of 11␤-HSD2 in the fetoplacental unit, notably the placental syncytiocytotrophoblast (152, 230, 231).
11␤-HSD1 is expressed at low levels in trophoblast tissue, although there is evidence for NADP-dependent dehydrogenase activity in human, baboon, and sheep trophoblast (232) (233) (234) . 11␤-HSD1 gene expression in the ovine placenta decreases as term approaches (149). 11␤-HSD1 is more abundantly expressed in chorion and decidua (152, 235, 236) .
Human and rodent endometrium expresses both 11␤-HSD isozymes (237) (238) (239) . 11␤-HSD1 expression in the sheep endometrium is low in the estrous cycle but increases markedly in pregnancy (240) . Decidualization of endometrial stromal cells is a fundamental process in implantation and invasion of the trophoblast. Estradiol and progesterone act, in a synergistic fashion, to induce 11␤-HSD1 expression in cultured endometrial stromal cells (241) . Glucocorticoids are known to regulate decidual matrix-degrading proteases such as collagenase and plasminogen activator, and this induction of expression of 11␤-HSD1 with the decidualization process may be of importance in this regard.
D. Cardiovascular system
Studies on patients with Cushing's syndrome (242) , and in subjects given hydrocortisone (243) , indicate that glucocorticoids play an important role in determining vascular reactivity in man, probably by potentiating the vasopressor action of endogenous catecholamines. MRs have been identified in the rabbit aorta and rat mesenteric vasculature (244, 245) . CBX and other 11␤-HSD inhibitors (including 11␤-HSD1 antisense oligonucleotides), through inhibition of dehydrogenase activity, potentiate noradrenaline and angiotensin II-induced vasoconstriction (25, 246, 247) , enhance vasoconstriction by reducing endothelium-dependent relaxation (248) , and increase Na ϩ / H ϩ exchanger activity in vascular smooth muscle cells (249) . However, in vivo, cortisol infusions in human studies have failed to produce any alteration in forearm vascular resistance with or without 11␤-HSD1 inhibition (250) . Furthermore, enhanced vasoconstrictor and impaired relaxation responses are observed in mice lacking 11␤-HSD2, but not 11␤-HSD1 knockout mice (251) .
To date, the evidence suggests that it is the 11␤-HSD1 isoform that is predominantly expressed in the vasculature, specifically in vascular smooth muscle and cultured rat aortic endothelial cells (25, 252, 253) , and here oxoreductase activity predominates (254) . Dehydrogenase activity is reduced in the mesentery of Dahl salt-sensitive hypertensive rats compared with the salt-resistant strain (255) . Expression is also reported in interstitial fibroblasts within the endocardium (256) . The expression of 11␤-HSD1 in these cells and in vascular smooth muscle cells has led to speculation that it might be involved in the pathogenesis of acute coronary vascular inflammation (257) . Additional studies are clearly warranted.
Aberrant expression of 11␤-HSD1 in other tissues may also result in a cardiovascular phenotype. Transgenic mice overexpressing 11␤-HSD1 develop hypertension as a consequence of increased circulating angiotensinogen (212) .
E. Gonad
1.
Ovary. Appreciable levels of 11␤-HSD have been detected in the rodent and human ovary (170, 258, 259) . Glucocorticoids are known to affect ovarian function in many ways, including inhibition of FSH-stimulated aromatase activity (260) , stimulation of the production of plasminogen activator in granulosa cells (261, 262) , and inhibition of LH-induced steroidogenesis from granulosa-lutein cells (263) . In rodent and human ovaries, 11␤-HSD1 is expressed in the developing oocyte and luteinized theca cells, whereas 11␤-HSD2 is found only in preovulatory, nonluteinized granulosa cells (170, 259, 264) . Treatment of granulosa cells at the time of ovulation with gonadotropins, human chorionic gonadotropin, and IL-1␤ stimulates 11␤-HSD1 expression in a dosedependent fashion (265) . IL-1␣ increased expression of 11␤-HSD1 mRNA and oxoreductase activity in human ovarian epithelial cells 3-fold, which was blocked with an IL-1 receptor antagonist (266) . The antiinflammatory role of glucocorticoids and its modulatory enzyme, 11␤-HSD, in the ovaries is reviewed by Hillier and Tetsuka (267) . Although the concept of developmental expression of 11␤-HSD enzyme in the ovaries has been widely accepted (170, 259, 268, 269) , there remains some debate as to the "directionality" of activity at this site. In bovine granulosa cells, 11␤-HSD1 mRNA expression inversely correlated with follicular fluid cortisol concentrations, suggesting dehydrogenase activity (270) . In the human, predominant reductase activity (269) or predominant NADP-dependent dehydrogenase activity (264, 271) has been reported. The kinetics of the dehydrogenase reaction are not entirely in keeping with 11␤-HSD1, but additional isozymes have not been characterized (264) . The expression of 11␤-HSD1 in cultured granulosa-lutein cells has been inversely correlated with pregnancy rates across in vitro fertilization cycles. Thus, in patients with detectable granulosa cell 11␤-HSD1-mediated dehydrogenase activity, pregnancy rates were zero, compared with a pregnancy rate of 76% in patients with no activity (272, 273) . In a subsequent study that detected dehydrogenase and reductase activities in granulose-leutein cells shortly before ovulation, no such correlation was observed (274) . However, a possible poor outcome in patients with detectable granulosa 11␤-HSD dehydrogenase activity, together with the expression of 11␤-HSD1 in the oocyte itself, would indicate that high local concentrations of cortisol are required for oocyte maturation. In keeping with these data, high concentrations of cortisol have been shown to be present in follicular fluid during the LH surge (275).
Testis and male reproductive tract.
High levels of 11␤-HSD1 were first described in the Leydig cells of the testis in 1965 (276) and subsequently confirmed by others (75, 122, 277). 11␤-HSD1 is not expressed in Sertoli cells but is present in the apical region of the principal epithelial cells of the caput epididymis, the epithelium of vas deferens, seminal vesicle, and penile urethra (278) . Glucocorticoids decrease testosterone production in mouse Leydig cell cultures (279, 280) , and inhibition of testicular 11␤-HSD dehydrogenase activity potentiates the inhibitory effect of corticosterone on testosterone secretion in rats (281) . The endogenous activity of testicular 11␤-HSD may explain male hormone-dependent behavior in the rat (282); dehydrogenase activity is higher in dominant male rats compared with controls and subordinates (283) . As with the ovary, there is ongoing debate as to the directionality of 11␤-HSD1 in the testis and the characterization of NADP-dependent dehydrogenase activity. Both dehydrogenase and reductase activities are reported. Leckie et al. (77) report almost exclusive reductase activity, but it is likely that reductase activity exceeds dehydrogenase activity in immature Leydig cells but dehydrogenase activity predominates in mature adult cells (284) . Differences in studies probably reflect the cell populations studied and culture media (285) . Protein kinase C induced dehydrogenase and decreased reductase activity, whereas calcium-dependent signaling mechanisms had the opposite effect (286) . However, studies have raised the possibility of a further putative 11␤-HSD isoform with high substrate affinity and NADPdependent dehydrogenase activity (287) . Recently, in vitro and in vivo, glucocorticoid-induced apoptosis has been shown in Leydig cells mediated by FasL/Fas and caspase-3 pathways (288, 289) .
F. Central nervous system and pituitary
High levels of NADP-dependent 11␤-HSD dehydrogenase activity have been detected in the rat brain, including the cerebellum, pituitary, and hippocampus. In situ hybridization and immunohistochemistry confirm this to be the 11␤-HSD1 isozyme (144, 290), and in one study, in cultured hippocampal neurons, the isozyme was shown to act predominantly as a reductase potentiating the neurotoxic effects of the inert glucocorticoid, 11-dehydrocorticosterone (72). Other studies (80, 291) have also supported the hypothesis that 11␤-HSD1 in the brain is acting primarily as a reductase. Despite elevated circulating corticosterone levels, 11␤-HSD1 knockout mice have decreased corticosterone levels within the hippocampus indicative of impaired glucocorticoid reactivation. It has been hypothesized that this is important in explaining their improved age-related learning impairments in comparison with controls (291). However, Jellinck et al.
(79) reported both reductase and dehydrogenase activities from intact hippocampus from rats under near-normal physiological conditions. Intracerebral microinjection into one or both lobes of the hippocampus revealed interconversion of tritium-labeled 11-dehyrocorticosterone and corticosterone. Additionally, in the hypothalamus/pituitary, inhibition of 11␤-HSD with glycyrrhetinic acid was shown to modulate the negative glucocorticoid feedback mechanism by inhibiting corticotropin-releasing factor concentrations within hypophysial portal blood (292) and also altered cerebral glucose metabolism (293) , all of which suggest functional dehydrogenase activity at these sites. Studies in the developing sheep pituitary support such observations (147). Similarly, in vitro in rat pituitary GH3 cells, inhibition of 11␤-HSD1 dehydrogenase activity by glycyrrhetinic acid potentiated the glucocorticoid-inhibitory effect on prolactin gene transcription (106) . In the normal human pituitary, 11␤-HSD1 expression is confined to GH-and prolactin-secreting cells and folliculostellate cells. Expression was absent in gonadotrophs, thyrotrophs, and, importantly, corticotrophs, suggesting that in normal physiology it does not modulate HPA axis glucocorticoid-negative feedback, at least at an autocrine level (294) . However, 11␤-HSD1 knockout mice do display abnormalities of the HPA axis. These animals have elevated corticosterone and ACTH levels, enhanced responses to stress, and insensitivity of HPA axis suppression with exogenous cortisol. Importantly, glucocorticoid-sensitive gene expression is not increased (295) . The conclusion from these studies is that local active glucocorticoid regeneration in this rodent model is an important regulator of HPA axis function.
Cortisol metabolism may have a role in pituitary tumor tumorigenesis. 11␤-HSD1 mRNA and activity are reduced to approximately 30% of normal levels in pituitary tumors (see Section VII.I) (296) .
G. Bone
Glucocorticoids have profound, yet potentially opposing, effects on bone. In vitro they are required for the differentiation of osteoblasts but in excess can cause suppression of the mature osteoblast phenotype by reducing proliferation and inducing apoptosis (297, 298) . Similarly, in vivo, glucocorticoids are anabolic at physiological concentrations, but in excess have an adverse effect on the skeleton, most clearly seen in glucocorticoid-induced osteoporosis. As a potential amplifier of glucocorticoid action in bone, 11␤-HSD isozyme expression has recently been examined in this tissue.
The first description of a relationship between 11␤-HSD and bone came with the description of a rickets phenotype in a child with apparent mineralocorticoid expression (299) . The bone problems appeared to be due to the metabolic alkalosis rather than any abnormality of intracellular glucocorticoid levels because this was reversible with spironolactone treatment. 11␤-HSD2 expression was next demonstrated in human fetal osteoblasts at midgestation using in situ hybridization and immunohistochemistry (300). 11␤-HSD2 mRNA expression and enzyme activity were further demonstrated in a range of rat and human osteosarcoma cell lines (301, 302) . Expression of this enzyme had important functional consequences, reducing expression of alkaline phosphatase in response to corticosterone treatment. [Indeed, based largely on these preliminary characterization data, transgenic mice have been created overexpressing 11␤-HSD2 in osteoblasts via the Col1a1 promoter: studies confirm the important anabolic role of glucocorticoids in bone using this model (Ref. 303 , and B. Kream, personal communication).] However, in contrast to its more restricted expression in adult life, it is now established that 11␤-HSD2 expression is widespread during fetal development. Additionally, expression of 11␤-HSD2 has been demonstrated in a range of cultured cell lines and is thought to be a manifestation of the malignant phenotype (304) (see Section VII.I).
That 11␤-HSD1 rather than 11␤-HSD2 was the major glucocorticoid-modifying enzyme in bone was suggested by the observation that differentiation of rat and mouse calvarial osteoblasts could be induced by cortisone treatment (305) . This effect was partially blocked by a nonselective 11␤-HSD1 inhibitor, CBX. Furthermore, in cultures of osteoblasts derived from adult female and male rat vertebrae, 11␤-HSD activity was detectable, but this activity was exclusively oxoreductase (306) .
Expression of 11␤-HSD1 has now been assessed directly in human bone and primary osteoblast cultures (301, 307, 308) . Here, 11␤-HSD1 mRNA expression and enzyme activity were present, and bidirectional enzyme activity was apparent. No 11␤-HSD2 mRNA expression or enzyme activity was present in these cultures. A detailed characterization of 11␤-HSD1 in adult bone demonstrated both dehydrogenase and reductase activities in chips of normal fresh bone, but kinetics of the reactions (bidirectionality and preference for a higher substrate concentrations) strongly supported the expression of 11␤-HSD1 and not 11␤-HSD2 (307) . In homogenates of human bone (in which endogenous cofactors are released) enzyme activity could be restored with NADP but not NAD, again indicating 11␤-HSD1 expression. Abundant 11␤-HSD1 mRNA expression by RT-PCR was also evident in fresh human bone obtained at orthopedic surgery. Immunohistochemistry and in situ hybridization using specific probes demonstrated expression of 11␤-HSD1 in osteoblasts and bone-lining cells, whereas expression in fibroblasts and adipocytes was low. 11␤-HSD2 expression under similar conditions was very low. Interestingly, 11␤-HSD1 expression was also seen in some (but not all) osteoclasts.
Several additional studies have replicated the expression of 11␤-HSD1 in adult human primary osteoblasts in which the activity is primarily reductase. The in vitro regulation of this activity has been explored. The proinflammatory cytokines TNF␣ and IL-1 increase 11␤-HSD1 mRNA expression and enzyme activity in a dose-dependent manner in primary osteoblasts and MG-63 osteosarcoma cells (309) . Cortisol and dexamethasone (100 nm) were also found to induce a 2-fold increase in 11␤-HSD1 activity and mRNA expression in primary human osteoblasts (308) , but the cellular basis for this increase was not examined (310) . More provocatively, 11␤-HSD1 expression in primary cultures of osteoblasts obtained from orthopedic operations appeared to increase with the donor age with an approximate 3-fold difference between young and old donors (Fig. 6A) (308) .
The potential functional impact of 11␤-HSD1 expression has been assessed in vivo in a small number of clinical studies. Short-term (7 d) inhibition of 11␤-HSD activities with CBX in normal volunteers had no impact on bone formation markers but did result in a suppression of the bone resorption markers, pyridinoline and deoxypyridinoline (307) . Whether these effects were due to direct inhibition of 11␤-HSD1 in osteoclasts (which mediate bone resorption) is unclear. The impact of selective inhibitors of 11␤-HSD1 activity is awaited with interest. It is possible that 11␤-HSD1 expression within osteoblasts could account for differences between individuals in the sensitivity of bone to therapeutic glucocorticoids in a clinical setting. In primary human osteoblasts the most widely used therapeutic glucocorticoids, prednisone and prednisolone, are metabolized by 11␤-HSD1 (Fig. 6B) with kinetics indistinguishable from those of the established endogenous glucocorticoids, cortisone and cortisol (308) . The impact of 11␤-HSD activity on susceptibility to glucocorticoid-induced changes in biochemical markers of bone turnover has been assessed in normal volunteers taking a moderate dose of prednisolone orally (311) . Systemic 11␤-HSD1 activity measured by the urinary THFϩallo-THF/THE ratio before steroid treatment strongly predicted the extent of the fall in bone formation markers (osteocalcin and N-terminal propeptide of type I collagen) at 4 and 7 d (Fig. 6C) . These relationships did not appear to be mediated by changes in systemic levels of glucocorticoids or total corticosteroid metabolite production. These data support the possibility that simple measures of 11␤-HSD1 activity may predict the development of bone-related adverse effects of systemic glucocorticoids during treatment. This hypothesis will need further exploration, especially given the potential changes in expression of 11␤-HSD1 that may occur during inflammatory conditions that necessitate systemic glucocorticoid treatment.
H. Eye
Topical and systemic glucocorticoids are used in a diverse range of conditions in clinical ophthalmology, and one of the most significant complications is corticosteroid-induced glaucoma. This condition is characterized by a significant increase in intraocular pressure (IOP), which, if untreated, can lead to visual field loss and blindness. Nearly one third of the normal population and virtually all patients with normal tension or primary open-angle glaucomas will develop raised IOP after topical steroid therapy (312) . IOP is maintained by a balance between production and drainage of aqueous humor. The major site of aqueous production is from the nonpigmented epithelial cells (NPE) of the ciliary body, whereas drainage is predominantly through the cells of the trabecular meshwork. The eye represents an important target tissue for corticosteroids, expressing both the MR (313) and GR (314) . Corticosteroids have long been implicated in the natural diurnal variation of IOP, and raised IOP may also occur in patients with Cushing's syndrome (315) . Several groups have used immunohistochemical and in situ hybridization analyses to assess the expression of 11␤-HSDs in a variety of human ocular tissues and have produced conflicting results. One study localized mRNA and protein for 11␤-HSD2 in the NPE, with coexpression of MR (316) . Because the NPE has morphological characteristics of epithelia engaged in salt and water transport, this, perhaps, was not surprising. However, Stokes et al. (317) and Rauz et al. (318) localized 11␤-HSD1 to this tissue type, suggesting that it is this isozyme that has an important role in aqueous humor production. Rauz and co-workers also demonstrated mRNA for GR, MR, and 11␤-HSD1 (but not 11␤-HSD2) in the human, ciliary epithelial cell line, ODM-2. Additionally, they noted that aqueous humor concentrations of "free" cortisol greatly exceeded those of cortisone (by gas chromatography/mass spectrometry analysis: cortisol-cortisone ratio, 14:1, compared with circulating F/E ratio of ϳ3:1). This would be consistent with local 11␤-HSD1 activity generating cortisol from cortisone. The functional significance of 11␤-HSD1 in the eye was then investigated by administering a nonspecific 11␤-HSD inhibitor, CBX, to healthy volunteers. After 7 d of CBX, IOP fell by 17.5%, in keeping with the hypothesis that inhibition of 11␤-HSD1 within the NPE reduces local cortisol generation, causing a fall in IOP. More recently, Rauz et al. (319) confirmed their earlier work by showing expression of 11␤-HSD1 within the NPE using in situ hybridization. They also found mRNA for 11␤-HSD1, but not type 2 in ciliary body tissue of patients undergoing surgical enucleation. Additionally, they showed that aqueous humor levels of cortisol were consistently higher than those of cortisone in both patients with primary open-angle glaucoma and controls, although levels were no different between these two groups. Finally, randomized, placebo-controlled studies of healthy controls and patients with ocular hypertension, revealed that systemic CBX for 4 d significantly lowered IOP by 10% (319) .
An important application of these findings could be in the therapeutic management of glaucoma, with topical prepa-rations of CBX or more selective 11␤-HSD1 inhibitors, effective in lowering IOP. However, a more critical analysis defining the role of 11␤-HSD in regulating epithelial sodium transport within the eye and its expression in glaucoma is now required.
I. Malignant tissues
Although 11␤-HSD1 expression and activity have been described for a diverse array of tissues, the enzyme is notable for its absence in tumors and tumor-derived cell lines (296) . For example, normal pituitary tissue shows strong expression of 11␤-HSD1, particularly in GH-and prolactin-secreting cells (294) . Conversely, expression of the enzyme in pituitary adenomas is greatly diminished, with a concomitant induction of 11␤-HSD2 expression (294, 296) . In a similar fashion, bone biopsies and primary cultures of osteoblastic cells have clearly defined expression of 11␤-HSD1 (301, 309) whereas osteoblastic cell lines derived from osteosarcomas express only 11␤-HSD2 (301, 302) . Other reports have described decreased expression of 11␤-HSD1 in squamous cell carcinomas of the head and neck compared with nonaffected mucosal tissues (320), whereas adrenal adenomas show strong induction of 11␤-HSD2 without a concomitant decrease in 11␤-HSD1 (321) . Studies in vitro suggest that this switch in isozyme expression may manifest itself through opposing effects on cell proliferation and differentiation (189): 11␤-HSD1 acts to decrease cell proliferation by raising local levels of antiproliferative cortisol, and 11␤-HSD2 pro- FIG. 6 . A, 11␤-HSD1 reductase activity increases with donor age in cultured human osteoblasts. B, Oral administration of prednisone (inactive) or prednisolone (active) results in significant exposure of active glucocorticoid to human bone through the activity of 11␤-HSD1 in osteoblasts. C, 11␤-HSD1 activity as measured by urinary corticosteroid metabolites predicts the fall in bone formation (osteocalcin) caused by exogenous glucocorticoid administration.
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vides a proproliferative signal by deactivating cortisol. As yet, the precise mechanism by which expression of 11␤-HSD1 is lost in neoplastic cells remains unclear, although key factors associated with the transcriptional regulation of 11␤-HSD1 such as CEBPs are known to be dysregulated in some tumors (322) . Another potential link between 11␤-HSD1 and cancer has developed from studies of purified, membranebound enzyme, which showed that 11␤-HSD1 is able to metabolize nanomolar concentrations of the tobacco-specific NNK, a known carcinogen. These studies have also raised important questions concerning the potential impact of 11␤-HSD inhibitors on tumor development. In the case of NNK, 11␤-HSD inhibitors such as glycyrrhetinic acid might promote tumorigenesis by decreasing the potential of 11␤-HSD1 to metabolize nitrosamines. By contrast, glycyrrhetinic acid has also been shown to act as an antiproliferative agent in 11␤-HSD2-expressing cancer cell lines (323) . In this case the putative mode of action is to moderate the inactivation of antiproliferative cortisol.
J. Immune tissues
Immunomodulation represents an important facet of glucocorticoid physiology and inflammation therapy and is manifested by the regulation of cytokine production and immune cell function (324) . In common with other target tissues, the ability of glucocorticoids to achieve these effects is likely to be dependent on the local regulation of glucocorticoid metabolism. This was recognized more than a quarter of a century ago by Dougherty et al. (325) , who first described the metabolism of active glucocorticoids in spleen and lymph tissues from rats. Subsequent studies have described expression of protein for 11␤-HSD1 in rat spleen and lymph nodes, and the conversion of corticosterone to 11-dehydrocorticosterone in various immune tissues, notably spleen, lymph nodes, Peyer's patch, and thymus (326) . However, it should be emphasized that these studies were carried out using homogenates from lymphoid tissues and, as such, it is difficult to make firm conclusions about the relative importance of reductase vs. dehydrogenase activity at these sites. In the rat immune system, the principal source of 11␤-HSD1 activity appeared to be the stromal cells associated with the spleen, thymus, or lymph nodes. However, transcripts for 11␤-HSD1 have also been detected in human lymphocyte (327) and macrophage preparations (328) . Importantly, in the latter study, Thieringer et al. demonstrated increased expression and reductase activity of 11␤-HSD1 during the differentiation of monocyte-derived macrophages. These data suggest a role for 11␤-HSD1 in macrophage-driven innate immune responses. However, induction of macrophage 11␤-HSD1 may also be linked to acquired immune responses: 11␤-HSD1 activity is enhanced by the T helper cell type 2 (Th2) cytokines IL-4 and IL-1, with this effect being abrogated by interferon-␥, a Th1 cytokine (328) .
11␤-HSD1, in turn, may influence the expression of Th1 and Th2 cytokines. At least in the rat, 11␤-HSD activity appears to be highest in tissues (spleen and peripheral and mesenteric lymph nodes) with a high proportion of Th1 T cells, and lower in tissues (Peyer's patch, thymus) in which T cells produce predominantly Th2 cytokines. Furthermore, inhibition of 11␤-HSD1 in lymphoid organs results in a shift from expression of Th1 cytokines (IL-2, interferon-␥) to Th2 cytokines (IL-4, IL-10) (329). The authors concluded that this reflected a glycyrrhetinic acid-induced decrease in glucocorticoid inactivation such that the increased concentration of glucocorticoids in lymphoid tissue stimulated a shift toward a Th2 phenotype, with a concomitant suppression of hypersensitivity responses. By contrast, other studies have reported depressed natural resistance to infection by Listeria monocytogenes after treatment with glycyrrhetinic acid (330) . Thus, the initial conclusion that lymphoid 11␤-HSD1 acted to support Th1 responses via dehydrogenase inactivation of glucocorticoids may be somewhat simplistic, particularly as glucocorticoids are potent generators of regulatory T cells, which play a key role in immune tolerance (327) .
In view of the expression of 11␤-HSD1 in a wide variety of immune tissues, it is perhaps not surprising that pathophysiological dysregulation of immune 11␤-HSD activity has also been demonstrated. In rodent and humans, abnormal cortisol metabolism has been reported after infection with tuberculosis (TB): analysis of urinary corticosteroids reveals an increase in cortisol rather than cortisone metabolites (331) . In addition, generation of cortisol from oral cortisone is higher in patients with active, rather than cured, pulmonary TB. Lastly, cortisol-cortisone ratios in bronchoalveolar lavage fluid (although not in serum) were increased in active TB groups compared with cured patients (332) . It has therefore been hypothesized that enhanced cortisol generation may be responsible for the immunoparesis that is observed in pulmonary TB.
K. Other tissues
The human and rodent adrenal expresses 11␤-HSD1 with highest expression seen in the zona reticularis at the corticomedullary junction (170, 333, 334) . It is possible that the high expression of 11␤-HSD1 at the corticomedullary junction facilitates the high intraadrenal glucocorticoid concentrations required for medullary catecholamine biosynthesis. Aldosterone-secreting adrenal adenomas also express high levels of 11␤-HSD1, and it has been hypothesized that enhanced reductase activity and cortisol generation promote steroidogenic activity within these tumors (334) .
In the lung, Northern blot analyses and assays of reductase activity (71, 151, 335) suggest the presence of 11␤-HSD1. Expression is highest in interstitial fibroblasts but also in type II pneumocytes. Within the fetal rat lung, corticosteroids increased 11-oxoreductase activity, which in turn resulted in an increase in surfactant synthesis (71), a glucocorticoiddependent process (336) essential for normal lung maturation. In addition, inhibition of 11␤-HSD1 with glycyrrhetinic acid in pregnant rats significantly impaired lung maturation and decreased surfactant production in the fetus (335) . Additional evidence to support a role for 11␤-HSD1 in lung maturation is found in studies in 11␤-HSD1 knockout mice. These animals have lower surfactant protein A concentrations, decreased surfactant production, and decreased amniotic fluid in comparison with wild-type animals (337) .
11␤-HSD1 is expressed in both human and rodent islets of Langerhans as well as rodent acinar cells (338) . Activation of 11-dehydrocorticosterone by 11␤-HSD1 in isolated rodent ␤-cells inhibited insulin release, an effect that was prevented by inhibition of 11␤-HSD1 with CBX. An autocrine-regulatory role in the control of insulin release has therefore been postulated (338) .
VIII. CRD
A. Clinical features CRD was first described in 1984. To date, 11 cases have been described, the majority of which are female. Detailed clinical and biochemical data for the published cases are presented in Table 5 . Female patients have invariably presented in adolescence or early adulthood with features of hyperandrogenism (acne, hirsutism, oligomenorrhea, infertility). Obesity has been a feature of some cases. Males have presented with precocious puberty. Serum androgens (dehydroepiandrosterone sulfate, androstenedione, and testosterone) have been elevated in each case, but readily decline after dexamethasone administration. Patients display a defect in the conversion of cortisone to cortisol, suggesting inhibition of 11-oxoreductase activity and therefore, by implication, inhibition of 11␤-HSD1. Indeed, CRD represents the putative "human 11␤-HSD1 knockout." Studies indicate an increased excretion of total cortisol metabolites indicative of enhanced cortisol secretion rates, often to values reported in patients with Cushing's syndrome. However, virtually all the urinary metabolites are excreted as 11-oxo-metabolites (THE, THA) with very low/undetectable levels of THF and allo-THF appearing in the urine. Typical THFϩallo-THF/ THE ratios, therefore, of Ͻ0.05 (normal adult range, 0.7-1.3) have been reported. (It is of interest that similar patterns of cortisol metabolism are observed in the normal neonatal period.) These data, together with an attenuated plasma cortisol response after oral cortisone acetate, suggest defective 11-oxoreductase activity (and thus 11␤-HSD1 activity). The defect in E to F conversion results in an increased metabolic clearance rate for cortisol; through the negative feedback mechanism, ACTH secretion is increased to maintain normal circulating cortisol concentrations, but at the expense of ACTH-mediated androgen excess. Dexamethasone suppresses endogenous ACTH and adrenal androgen levels, thereby explaining its therapeutic role in CRD. Although this biochemical evidence strongly implicated a defect in 11␤-HSD1 as being causative in the syndrome of CRD, it is only recently that the molecular basis for the disease has been defined.
B. Molecular basis for CRD and directionality of 11␤-HSD1
The mode of inheritance of CRD is thought to be autosomally recessive, as two sets of sib-pairs have been identified without affected parents. Analysis of genomic DNA has been undertaken in a number of patients to try and determine a mutation within HSD11B1. Southern blot analysis of HSD11B1 from one CRD patient showed no gross deletions or rearrangements (339) . In addition, further sequencing of the coding region of HSD11B1 within four CRD patients revealed no mutations (339 -342) .
Recently, we have reported an extensive genetic investigation of HSD11B1 in three CRD kindreds, each with a single affected case. The CRD cases, one of which is male, all exhibited characteristically low urinary THFϩallo-THF/THE ratios of between 0.03 and 0.04 (reference range, 0.7-1.1) and have been described previously in the literature (340, 343, 344) . We also reported the first analysis of 11␤-HSD1 mRNA levels and enzyme activity in tissue from a CRD subject. We failed to identify mutations in the six exons of HSD11B1 in affected cases. The same was true for 1.5 kb of the HSD11B1 promoter and introns 1, 2, and 5. However, in all three CRD cases, two polymorphisms in complete linkage disequilibrium within intron 3 of HSD11B1 were identified: an A insertion (83557) and, 40 bp downstream, a T to G substitution (83597). The allele frequency for the 83557A/83597T-G haplotype was 14% in control populations (84) .
Although the 11␤-HSD1 cDNA sequence was normal in case 1, adipose tissue mRNA levels were 28-fold lower when compared with an unaffected sister, and corresponding oxoreductase activity was absent (0% conversion of E to F vs. 14% in the unaffected sibling). In luciferase reporter assays, there was a 2.5-fold reduction in transcriptional activity in HSD11B1 constructs containing the intron 3 83557A/ 83597T-G mutation compared with wild type, suggesting that this region of the gene acts as an intronic enhancer of HSD11B1 expression. These data are in keeping with published precedents suggesting a silencer/enhancer role for intronic sequences in many genes including HSD11B2 (345) . The impact of heterozygosity for the 83557A/83597T-G mutation upon cortisol metabolism is unknown, but the CRD phenotype cannot be explained by heterozygosity or homozygosity at this single locus because this was present in 25% and 3% of normals, respectively.
As discussed in Section III.B, 11␤-HSD1 oxoreductase activity requires NADPH. The purified enzyme behaves as a NADP-dependent dehydrogenase (52), and the switch to oxoreductase activity upon tissue homogenization (83) suggests a close association between 11␤-HSD1 and a NADPH generation system. The glucose-6-phosphate dehydrogenase enzyme of the pentose phosphate pathway has been considered to be the major source of intracellular NADPH (346) , but this is a cytosolic enzyme and the membrane-binding domain of 11␤-HSD1 directs the active site of the enzyme toward the ER lumen, away from the cytosol (54, 85, 347) . Here H6PDH, an enzyme of previously uncertain significance but related to glucose-6-phosphate dehydrogenase, can catalyze the first two steps of the pentose phosphate pathway and generate NADPH (349, 350) . H6PDH is present in most tissues but is highly expressed in liver and adipose tissue, sites of 11␤-HSD1 oxoreductase activity (349, 351, 352) .
Sequencing of the H6PD gene, localized to chromosome 1p36. 2 (353) , revealed mutations within exon 5 in all three CRD cases. Case 1 was heterozygous for 620ins29bp621, an insert of 29 bp between residues 620 and 621 that results in the inclusion of three new amino acids and a stop codon, truncating the protein by 171 amino acids. Cases 2 and 3 were homozygous for R453Q, a nonconservative missense amino acid change. When H6PD mutant cDNAs were synthesized and expressed in hepatic WRL68 cells, the 620ins29bp621 mutant was devoid of H6PDH activity, and the R453Q mutant demonstrated residual activity that was consistently less than 50% of wild type. The impact of the R453Q mutation in the context of a normal HSD11B1 genotype is unknown. The allele frequency of R453Q in both Scottish and Indo-Asian controls is 21-22%, so that approximately 4% of the normal population is homozygous for this mutation. The combination of homozygosity for the H6PD R453Q and heterozygosity for the HSD11B1 intron 3 83557A/83597T-G mutations was not observed in our control subjects, and its presence in two of the three CRD patients is unlikely to be due to chance (P ϭ 0.0008, Fisher's exact test). Based on our normative allelic frequency data, we can predict a prevalence rate for CRD of approximately 0.1% for the mutations HSD11B1 ϩ/Ϫ and R453Q H6PD Ϫ/Ϫ . Alternatively, interaction with an unidentified third locus, modifying penetrance, might be implicated.
Thus, a combination of mutations in the HSD11B1 and H6PD genes interacts to cause CRD manifesting in a reduction in 11␤-HSD1 expression and impaired provision of NADPH to an enzyme that is critically dependent on reduced cofactor for oxoreductase activity (Fig. 1A) . A digenic triallelic mode of inheritance is proposed, in which three distinct alleles, from two (or more) loci (HSD11B1 and H6PD) are necessary for trait manifestation.
IX. HSD11B1 Linkage and Association Studies
A. Obesity
Strong evidence for a genetic component to obesity is provided through studies of correlations in BMI and other adiposity measures between family members, adoptees and their biological relatives, and monozygotic and dizygotic twins. In fact, the genetic effect on visceral fat (adjusted for fat mass) has been calculated from twin studies to account for about 50% of the phenotypic variance (354) . Monogenic forms of obesity due to mutations, notably in the genes encoding leptin, leptin receptor, MCR4, and proopiomelanocortin, have been described. However, the role of genetic factors in common obesity is likely to be polygenic, comprising an interaction between several susceptibility genes that individually have small effects (355) . Indeed, more than 50 different loci have been linked to obesity through genome scan and linkage studies including loci on chromosome 1 (355) .
The characterization of polymorphisms within the human HSD11B1 gene has enabled an evaluation of this locus as a susceptibility factor for obesity. Genotyping of a large normal population demonstrated a lack of association between the HSD11B1 gene and BMI, but a weak association was observed with waist-to-hip ratio (WHR) in women. Similarly, in a case-control association study evaluating a group of Danish obese subjects, no relationship between allelic variation at these microsatellite loci and BMI was observed (131). However, the link between glucocorticoids and adipose tissue biology primarily relates to adipose tissue distribution rather than absolute fat mass. Although urinary steroids were not analyzed in the Danish ADIGEN study, a borderline significant association was found between long alleles for a CA 15 microsatellite marker and short alleles for an adjacent CA 19 marker with a raised THFϩallo-THF/THE ratio and WHR in the montoring of trends and determinants in cardiovascular disease (MONICA) population. These data are compatible with increased 11␤-HSD1 activity predisposing to central obesity. However, a relationship between this allele distribution and central fat distribution was not evident in the ADIGEN study. HSD11B1 genotypes were similar in lean and obese groups, and no relationship was seen with allele length at the two polymorphic loci and BMI or WHR in either group. The lack of association seen in this study may be explained, in part, by the relatively poor heterozygosity rates for the (CA) n microsatellite markers, and other markers may prove more fruitful in future studies.
A study has screened the HSD11B1 gene-coding region and intron/exon boundaries for mutations in eight patients with abdominal obesity and four lean control subjects (130). No mutations were identified in the coding region; however, a polymorphism within an intron was identified: a deletion of 11 bp in intron 1 [position 441-451 of GenBank accession no. M76661 (exon 1)] was detected in all subjects studied. This polymorphism does not alter splicing and does not affect donor or acceptor splice sites (130). In a separate study, the intron 3 adenine insertion was identified and associated with pediatric obesity in a mutation screen of the HSD11B1 locus (356) . These data support our functional analyses of this mutation, as described in Section VIII.B., whereby the presence of the inserted A leads to a reduction in transcription and consequently a decrease in 11␤-HSD1 activity.
A recent study identified five common haplotypes within the 55-kb region surrounding HSD11B1 from 96 chromosomes. Family trio samples (350) were reported with extremes of WHR. A SNP in the 5Ј-untranslated region of HSD11B1 was associated with WHR, the minor allele being associated with lower WHRs (357) .
Interestingly, the obesity gene map includes several studies that have implicated the chromosomal loci 1p36.2-1p36.3, the H6PDH chromosomal location, for association with obesity (355) .
B. Other diseases
Genetic analysis of HSD11B1 in CRD patients may provide an important candidate gene for future analysis in larger more heterogeneous polycystic ovary syndrome (PCOS) population studies. It is accepted that PCOS has a genetic component, although most likely working in concert with environmental factors (358, 359) . Epidemiological studies show that PCOS is a familial disorder with a sibling risk of 50 -80% (360, 361) . Twin studies have shown discordance for polycystic ovaries, suggesting that PCOS might have a complex inheritance pattern, and segregation analyses within families propose polygenic influences confounded by environmental factors (362) . However, a single gene may have a predominant effect in a given family. With the reported partial defects in 11␤-HSD1 in patients with PCOS (363), it will be of interest to determine whether the HSD11B1 gene (and/or the H6PD gene) acts as important susceptibility loci in this regard.
Primary open-angle glaucoma has a significant hereditary component (364, 365) , and several genetic loci, many of which are located on chromosome 1q, have been linked to its pathogenesis (366) . Mutations of the myocilin/trabecular meshwork-inducible glucocorticoid response account for most, but probably not all, of these cases, and other additional pathological factors may be implicated. Interestingly, HSD11B1 is localized to 1q32-41.
The recent identification of 11␤-HSD1 in human bone has raised the possibility that it may be implicated in the pathogenesis of age-related and glucocorticoid-induced osteoporosis. Several candidate genes have been identified as being important in the pathogenesis of osteoporosis (367), but to date there are no large genetic studies that have assessed the contribution of 11␤-HSD1. However, the cytogenetic localization of H6PD gene, 1p36, has been implicated for association with hip and femoral neck bone mineral density in several genome-wide scans (368, 369) .
X. Conclusions
11␤-HSD isozymes serve an important function in cortisol metabolism and clearance. However, based on the important precedent of 11␤-HSD2 and the control of renal cortisol concentrations, a series of in vitro, in vivo, and clinical studies have now defined the pivotal role that 11␤-HSD1 plays in modulating glucocorticoid hormone action in many tissues. Interest has principally focused on the liver and adipose tissue and the regulation of hepatic gluconeogenesis and fat mass. As a consequence, 11␤-HSD1 has emerged as an exciting novel therapeutic target in the metabolic syndrome, and the results of trials employing selective 11␤-HSD1 inhibitors are anxiously awaited. The role of 11␤-HSD1 in other diseases including osteoporosis and glaucoma is under evaluation.
Unlike its type 2 counterpart, 11␤-HSD1 is a bidirectional enzyme, and the elucidation of the molecular basis for the "human 11␤-HSD1 knockout" (i.e., CRD) has uncovered the crucial enzyme that conveys reductase activity upon 11␤-HSD1 (i.e., H6PDH). In turn, this has opened up new avenues of research in terms of intracellular redox control and its impact upon cellular metabolism.
More than 50 yr ago Hench, Kendall, and Reichstein shared the Nobel prize for their discovery of cortisone and description of its antiinflammatory properties in patients with rheumatoid arthritis, thereby establishing the endocrine importance of 11␤-HSD1. Today 11␤-HSD1 is also established as an important "prereceptor" regulator of glucocorticoid action at an autocrine level. Targeted inhibition of the enzyme may reduce the action of cortisol in key tissues without resulting in the deleterious consequences of circulating cortisol excess or deficiency. 
